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Due to its ability to probe water-containing samples using visible and near-infrared 
frequencies with high chemical specificity, Raman spectroscopy is an attractive 
tool for label-free investigation of biological samples. While Raman spectroscopy 
has been leveraged for exploratory studies in clinical cancer diagnostics, only 
limited studies have used it to understand the molecular mechanisms driving key 
characteristics of cancer progression. In this thesis, we present three progressively 
complex applications of Raman spectroscopy that take advantage of its specificity 
and synergistic combination with plasmonic nanoparticles and multivariate data 
analysis for molecular study of cancer. 
First, we used Au@SiO2 shell-isolated nanoparticle-enhanced Raman 
spectroscopy (SHINERS) to investigate the roles of microcalcification status and 
the composition of tumor microenvironment in breast tissue for identification of a 
range of breast pathologies. We developed a partial least squares-discriminant 
analysis-based classifier to correlate the spectra with their pathology to obtain high 
prediction accuracy. A parallel investigation of the genetic drivers of 
microcalcification formation in breast cancer cells revealed that stable silencing of 
the Osteopontin gene decreased the formation of hydroxyapatite in breast cancer 
cells and reduced their migration. 
Next, we demonstrated the ability to detect premetastatic changes in the 
lungs of mice bearing breast tumors, in advance of tumor cell seeding, using 
Raman spectroscopy and multivariate data analysis. Our measurements showed 
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reliable differences in the collagen and proteoglycan features of the premetastatic 
lungs which uniquely identify the metastatic potential of the primary tumor. 
Consistent with histological assessment, our results hint at a continuous 
premetastatic niche formation model dependent on the metastatic potential of 
primary tumor. 
Finally, we exploited Raman mapping to elucidate radiation therapy-
induced biomolecular changes in murine tumors and uncovered latent 
microenvironmental differences between treatment-resistant and -sensitive tumors. 
We used multivariate curve resolution-alternating least squares (MCR-ALS) and 
support vector machine (SVM) to quantify biomolecular differences in the tumor 
microenvironment and constructed classification models to predict therapy 
outcome and resistance. We found significant differences in lipid and collagen 
content between unirradiated and irradiated tumors. 
 Taken together, these studies pave the way for applications of Raman 
spectroscopy beyond clinical diagnostics such as metastatic risk assessment and 
treatment monitoring. 
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Introduction to biomedical Raman spectroscopy 
  
The diagnostic tools currently used in clinical practice largely rely on subjective 
evaluation of morphological manifestation of diseases. However, biochemical 
modifications often precede morphological changes in a variety of pathological 
transformations including cancer. A majority of laboratory techniques currently 
used to analyze the chemical make-up of biological samples are either too labor 
intensive or require operator expertise, which makes their clinical translation 
challenging. Powered by excellent chemical specificity and lack of extensive 
sample preparation requirements, Raman spectroscopy has emerged as an 
attractive solution for label-free characterization of biological systems both in vivo 
and ex-vivo/in vitro settings in a non-invasive or minimally invasive manner. 
1.1 Raman spectroscopy 
Raman spectroscopy, an inelastic optical scattering technique, was first 
discovered in 1928 by Sir C. V. Raman [1]. When monochromatic light is scattered 
by molecules, the elastically scattered photons are accompanied by lower or 
higher frequency photons (inelastically scattered light) due to changes in the 
vibrational states of the molecules under investigation. While a majority of photons 
undergo elastic scattering, a very small proportion lose energy (Stokes shift) and 
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an even smaller proportion gain energy (anti-Stokes shift) at room temperature 
depending on the changes in vibrational states of the molecules (Fig. 1.1) [2, 3]. 
Most biological and biomedical investigation probe Stokes Raman scattered 
photons due to their relative abundance at room temperature. Consequently, 
biological Raman spectra in this region show strong fluorescence background due 
to excitation of endogenous chromophores in the samples. Since Raman 
spectroscopy doesn’t require excitation of molecules to the stationary electronic 
states, a range of frequencies from deep UV to NIR region can be used for 
excitation depending on other considerations such as suppression of fluorescence, 
minimizing photodamage or maximizing penetration depth. This allows successful 
chemical structural fingerprinting of a variety of molecules independent of the 
excitation wavelength. 
 
Figure 1.1: Biomedical Raman spectroscopy. (A) The energy level transitions 
for Stokes and anti-Stokes Raman spectroscopy are shown in comparison with 
Rayleigh scattering on a Jablonski diagram. Reproduced from ref. 2 (Licensed 
under CC BY SA 4.0). (B) Mean and standard deviation of Raman spectra 
obtained from normal and cancerous tissue sites in 95 patients during clinical 
endoscopy. Reproduced from ref. 3 (Licensed under CC BY NC 4.0). (C) The 
difference Raman spectrum (i.e., cancer - normal) shows disease-specific features. 
Reproduced from ref 3.  
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For several decades since its discovery, Raman spectroscopy was largely 
confined to the analysis of simple systems like pure liquids and gases. However, 
with the advent of powerful, stable and tunable lasers and sensitive multi-channel 
detectors in the past couple of decades, Raman spectroscopy has emerged as a 
powerful tool for analysis of complex biological systems like cells and tissues. 
Some of the early biochemical characterization of small and macro- molecules 
using Raman spectroscopy laid the foundations of future medical applications [4]. 
Important investigations of amino acids, proteins and enzymes in solid and 
aqueous states by Lord, Koenig, Yu and others revealed important insights about 
their secondary structures [5-7]. Similar studies conducted by Lord, Thomas, 
Hirano and others characterized the Raman bands of nucleotides and nucleic 
acids [6, 8-10]. Early Raman study of calcified tissues such as bone and collagen 
by Walton and others revealed important Raman bands characteristic of the 
constituents such as calcium phosphate, inorganic carbonate, proline and 
hydroxyproline [11] . Later studies of physiological and pathological calcification 
observed during bone remodeling and breast cancer have benefited from these 
Raman bands. Other studies around this time utilized the strong resonance 
enhancement offered by the substances such as hemoglobin, cytochrome c and 
-carotene due to overlap of laser line with the electronic transitions [4]. Motivated 
by these observations, Raman studies of normal and diseased human tissues by 
several research groups soon followed in the 1990s. Several pioneering medical 
applications were focused on cancers of breast and brain, diabetic retinopathy, 
and mineralization, among others [12-17]. The ability to probe molecules in their 
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native physiological states, negligible interference from water in biological samples, 
use of non-ionizing radiation and ease of integration with other techniques makes 
Raman spectroscopy particularly suitable for noninvasive characterization of 
biological samples in vivo [18, 19]. Medical applications ranging from disease 
diagnosis to metastasis assessment, chemotherapeutic monitoring to non-invasive 
glucose sensing, have been demonstrated using this technique [20-27]. 
Due to the use of visible-near infrared light, the clinical translation of Raman 
spectroscopy for medical applications is impeded by challenges such as poor 
sensitivity, broad fluorescence background, and poor penetration depth. To tackle 
these challenges, several variants such as surface enhanced Raman 
spectroscopy (SERS), spatially offset Raman spectroscopy (SORS), resonance 
Raman spectroscopy, coherent anti-Stokes Raman spectroscopy (CARS), and 
stimulated Raman Spectroscopy (SRS) have been developed and employed to 
enhance sensitivity and selectivity of Raman measurements [27, 28]. In addition, 
the developments in fiber-optics probes and advances in nanotechnology and 
computation have been vital for the recent surge in medical applications of Raman 
spectroscopy and its variants. In this chapter, we will discuss a selection of medical 
applications that have harnessed the advantages offered by Raman spectroscopy. 
In the first part, important aspects of instrumentation used in typical Raman 
spectroscopy applications will be briefly reviewed. This section will be followed by 
a brief summary of popular methods that are employed at each step in the data 
analysis workflow. These include background removal, dimensionality reduction 
and classification methods that are routinely used to create diagnostic frameworks 
5 
 
based on Raman spectral data. Next, some variants of Raman spectroscopy that 
have been explored for medical applications are discussed to present the key 
advantages they provide over spontaneous Raman. In the final section, some 
representative studies demonstrating the feasibility of Raman spectroscopy in a 
wide range of pathologies and their key findings have been discussed. 
1.2 Instrumentation 
1.2.1 Illumination 
The complexity of biological media requires monochromatic and narrow line-width 
light sources and sensitive detectors for obtaining interpretable Raman spectra 
and simultaneously minimizing laser-induced photodamage (Fig. 1.2) [29]. 
Therefore, the medical applications of Raman spectroscopy were made feasible 
by the developments and advancements in laser technology. Today lasers 
spanning from deep-UV to near-infrared (NIR) with small form factor are routinely 
used for Raman spectroscopy. The lasers in the UV region are particularly suited 
for resonance Raman spectroscopy applications due to the matching of their 
energy with the electronic transitions and the existence of an autofluorescence-
free window in the deep UV region. However, they are not preferred for clinical 
Raman spectroscopy applications due to their propensity to cause photodamage. 
The lasers on the other end of the spectrum, NIR diode lasers (e.g. at 785 nm and 
830 nm) offer significantly lower sensitivity due to the inverse dependence of 
scattering (1/)4 on wavelength. Despite such disadvantage, existence of near 
absorption-free spectral window makes this region well-suited for tissue analysis 
by minimizing autofluorescence signal and maximizing the depth of penetration. 
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The lasers in the visible region offer higher Raman sensitivity than NIR sources 
while minimizing the laser-induced photodamage in comparison to UV sources for 
interrogation of systems such as single live cells, that are void of major biological 
chromophores. The compact assembly of modern semiconductor lasers allows for 
seamless integration of multiple lines spanning the spectrum from UV to NIR (and 
convenient switching between them) into laboratory Raman system. However, the 
portable clinical instruments built for endoscopy and surgical guidance often rely 
on a single NIR laser for tissue spectral acquisition. 
 
 
Figure 1.2: Schematic of a typical Raman spectroscopy system used for 
medical applications. Reprinted with permission from ref. 29. Copyright 2016 




The efficient collection of Raman scattered photons is very crucial for maximizing 
the throughput at minimal laser power and spectral acquisition time. The first 
critical step towards this is the rejection of elastically scattered light, which is 
typically accomplished by the use of edge or notch filters. Secondly, the 
decomposition of inelastically scattered light into constituent wavelengths 
(wavenumbers in Raman literature) is accomplished using diffraction gratings in 
most modern medical applications. The grating characteristics such as groove 
density (g/mm), focal length and groove profile play an important role in 
determining the spectral resolution of a Raman instrument. Typically, a single 
grating is sufficient to obtain spectra covering the fingerprint region at a satisfactory 
spectral resolution for clinical applications. Finally, the quantification of intensity at 
different wavenumbers is accomplished by focusing the dispersed radiation on a 
thermoelectrically cooled CCD. The CCDs are particularly suited for medical 
Raman spectroscopic applications in UV, visible and NIR regions due to their high 
quantum efficiency, low dark noise due to thermoelectrical cooling, and 
multichannel operation for the acquisition of complete spectrum in a single 
measurement. Furthermore, their compact architecture facilitates seamless 
integration of the resultant Raman spectroscopy systems with clinical workflow. 
1.2.3 Raman probes and handheld devices 
The effective delivery of laser and collection of backscattered Raman photons for 
disease diagnosis and surgical margin assessment has been made possible by 
developments in fiber optics technology [30]. Some of the key considerations in 
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the design of Raman probes include maximizing collection efficiency of Raman 
signal and minimizing background signal stemming from fiber material itself. Most 
clinical applications employ optical fibers made up of fused silica glass doped with 
index-raising materials for increasing the refractive index of the core for obtaining 
total internal reflection. A significant proportion of probes also employ hollow core 
waveguides, which are hollow glass tubes with their interior coated with metals for 
reflection. While they eliminate the glass fiber background and resultant shot noise, 
they are associated with much higher losses and lesser flexibility. In the 
construction of Raman probes, multiple such fibers with designated delivery and 
collection roles are employed along with other optical elements such as filters and 
lenses. By selecting appropriate geometry, optical elements and materials, the 
probe characteristics such as throughput and depth selectivity can be modulated 
to suit specific applications (e.g. probing surface vs. subsurface lesions). The 
optical fiber-based Raman probes have been employed for various endoscopic 
diagnosis applications. The miniaturization of instrumentation is critical for further 
clinical acceptance of the technology and its translation from laboratory bench to 
bedside. While several handheld Raman detection systems have been designed 
and implemented for field applications in industrial settings, only few have been 
tested for clinical applications [31]. Improvements in the sensitivity of completely 
handheld Raman systems can be very beneficial for timely detection of disease in 
accessible organs such as skin, cervix and oral cavity, even in low resource 
settings. The handheld Raman detectors can be integrated with the fiber optic 
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probes for delivery and collection of light from inaccessible regions such as breast, 
stomach and colon. 
1.3 Multivariate data analysis 
Raman spectra encode a wealth of molecular information stemming from the 
vibrational modes in a specimen. However, maximal utilization of the complex 
spectra obtained from biological samples that are composed of a large number of 
components requires systematic analysis of spectral datasets. Typically, Raman 
data analysis workflow includes steps such as preprocessing to remove spectral 
interferents, dimensionality reduction, and classification/regression. In this section, 
a selection of the most common data analysis techniques used in recent medical 
applications will be discussed.  
1.3.1 Preprocessing 
Background subtraction: Due to excitation of intrinsic fluorophores in the 
biological media [32, 33], the Raman spectra in the Stokes region are 
accompanied by a broad fluorescence background. Therefore, direct observation 
of weak Raman features amidst such overwhelming background is often not 
feasible. To tackle this, a variety of background removal methods have been 
reported [34]. The most common approach involves fitting a polynomial (e.g. fifth 
order) mimicking the broad background and subtracting it from the spectrum to 
uncover the weaker Raman features buried in it. Another method called 
asymmetric least squares that is used for background estimation and simultaneous 
smoothing relies on iterative minimization of the sum of the squared difference 
between the raw and estimated background signals using ordinary least squares 
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with a bias towards positive residuals. In frequency domain methods such as those 
based on Fourier and wavelet transformations, the slowly-varying background can 
be distinguished from sharp Raman features and removed by appropriate 
frequency thresholding. These methods also allow smoothing by identifying and 
eliminating the contribution of high-frequency noise components. While these 
methods help uncover the latent Raman features, caution must be exercised to 
ensure that subtle features of diagnostic importance are not lost due to background 
subtraction. Studies have shown that in the presence of uniform background 
across the entire spectral dataset, the downstream classification algorithms yield 
very similar results for spectra with and without background removal [29, 35]. 
Smoothing: The weak Raman features stemming from biological specimen are 
often accompanied by noise and cosmic rays. Therefore, to better visualize Raman 
peaks and distinguish them from noise, different smoothing methods are routinely 
employed in the data analysis pipeline, often after background subtraction. The 
most commonly implemented denoising technique, Savitzky-Golay method 
involves locally fitting a polynomial of specified order within a moving window of 
fixed size. As a result, the technique is highly sensitive to the choice of polynomial 
order and window size because choosing a large window size can lead to over-
smoothing and loss of important Raman features. Similarly, choosing a higher 
order polynomial in a small window can render the method ineffective due to 
overfitting and retention of noise. The other smoothing methods such as median 
filtering, wavelet transform, Gaussian filtering and methods based on rejection of 
high frequency components have been used for biomedical Raman data. 
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Normalization: Due to factors such as laser intensity fluctuations, differences in 
probe-sample distance and intensity fluctuations introduced by background 
subtraction, comparison of Raman spectra belonging to different samples acquired 
in non-uniform conditions can produce misleading observations. Therefore, there 
is a need to employ a suitable method for standardizing the spectra prior to 
analysis. This is often tackled by using intensity normalization using one of the 
many available techniques at one or more stages of Raman data analysis [34]. 
The most commonly employed normalization techniques for biomedical Raman 
data include peak normalization, vector normalization and min-max normalization. 
Traditionally, normalization of Raman spectra based on the intensity of a prominent 
peak stemming from an invariant component in the system-as an internal standard- 
was employed for comparison of the remaining peaks in a multi-component system. 
However, this method is not suitable for biological systems where identification of 
such an invariant component is difficult or where peak shifts are important 
indicators (e.g. evolution of protein structure). As a result, approaches such as 
min-max and vector normalization have been extensively used in the recent 
studies that set reasonable upper and lower bounds on the spectral datasets. In 
min-max normalization method, the maximum and minimum intensity levels of the 
spectra are made 0 and 1, respectively and the remaining intensities are scaled 
accordingly. However, in vector normalization, each spectrum is scaled to make 
its norm (typically Euclidean norm) unity. 
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1.3.2 Dimensionality reduction 
Typically, Raman spectra used for medical applications, in the fingerprint or high 
wavenumber region obtained at an appropriate spectral resolution, have hundreds 
of dimensions (wavenumbers). This high-dimensionality, coupled with the 
availability of a limited number of spectra due to long acquisition times makes 
careful dimensionality reduction important for avoiding the ‘curse of dimensionality’ 
and improving the classification accuracy. Principal component analysis (PCA) is 
the most commonly employed technique to achieve dimensionality reduction by 
projecting the spectral dataset onto an orthogonal set of basis vectors in the order 
of the variance in the data they explain. Such condensation of important spectral 
information into fewer dimensions enables selective rejection of contributions from 
broad background and noise in the spectra as they can be easily identified from 
the obtained set of principal components. In addition to making data visualization 
simpler, the low-dimensional data thus obtained also enhances the robustness and 
computational simplicity of the downstream analysis such as classification and 
regression. The graphical representation of projection scores as 2D and 3D scatter 
plots or multidimensional radial visualization plots are often used for qualitative 
assessment of clustering behavior or other consistent patterns in the biological 
Raman datasets. 
In addition to PCA, several other similar dimensionality reduction 
transformations such as independent component analysis (ICA), linear 
discriminant analysis (LDA) and partial least squares (PLS) have been used in the 
Raman literature to suit specific applications. Recently, multivariate curve 
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resolution alternating least squares (MCR-ALS) has emerged as an important tool 
for identification of key spectral constituents that resemble dominant pure 
components in multicomponent mixtures [36]. Along with dimensionality reduction, 
the use of positivity constraints in the determination of MCR components allows 
for a direct comparison of the projection scores to gain important insights into the 
chemical abundance of the associated pure components across the samples. 
Therefore, the technique helps unbiased recovery of putative molecular markers 
from a biological specimen (as opposed to only spectral markers) that can serve 
as targets for traditional bioanalytical techniques. 
1.3.3 Classification techniques 
To fully exploit the chemical specificity of Raman spectroscopy and retrieve 
important information of diagnostic significance from subtle spectral differences in 
the biological samples, several supervised and unsupervised classification 
algorithms have been reported for successful diagnosis and monitoring of closely 
related pathological states. In this section, the merits and limitations of the most 
widely used techniques will be discussed. 
Clustering methods: Clustering techniques provide an excellent opportunity for 
identification of intrinsic groupings and patterns in multivariate datasets, 
particularly in the absence of class labels. The two most popularly used methods 
in medical applications of Raman spectroscopy include k-means cluster analysis 
(KMCA) and hierarchical cluster analysis (HCA). In KMCA, based on the 
prescribed number of estimated classes and their centroids, the dataset is 
iteratively categorized into multiple clusters such that the distance between their 
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centroids is maximized. While KMCA is simple and elegant for datasets with 
distinct classes, it is not very suitable if there exists a hierarchy within the classes. 
To tackle such datasets, HCA performs binary splits of the dataset progressively 
at each level via either a top-down or a bottom-up approach in order to create a 
dendrogram. In the top-down approach, the entire dataset is split into two clusters 
and the resultant clusters are then divided into two more clusters and so on until 
the clusters become too small or similar to perform further splits. Similarly, in the 
bottom-up approach, the individual instances are treated as distinct clusters and 
combined progressively based on their similarity to finally merge into one large 
cluster (i.e. the complete dataset). Due to the availability of the entire hierarchically 
organized dendrogram, HCA doesn’t require the knowledge of the number of 
classes in the dataset. The ability to use these clustering methods before or after 
dimensionality reduction can help identification of key mediators of class 
separation in spectral datasets. 
Linear supervised classification: Several studies have successfully modeled 
Raman spectra of complex mixtures as a linear combination of the constituent 
spectra. Exploiting such linear relationships, several classification techniques that 
attempt to learn a linear plane separating the classes of interest have been 
adopted in biomedical applications of Raman spectroscopy. Linear discriminant 
analysis (LDA) and its variants are the most widely used methods for distinguishing 
closely related pathological states. The key assumptions about the data that allow 
the application of LDA include multivariate normality of each variable and equal 
covariance for all the classes. The lack of a sufficient number of instances 
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compared to the dimensionality of spectra often encountered in Raman datasets 
makes direct application of LDA challenging due to the potential occurrence of non-
full rank estimates of covariance matrices. This problem is often avoided by 
incorporating an appropriate dimensionality reduction method such as PCA to 
project the spectral dataset onto a low-dimensional space prior to applying LDA. 
Another widely used method in the biomedical Raman spectroscopy applications, 
partial least squares discriminant analysis (PLS-DA), attempts to find a 
discriminatory hyperplane by projecting both the spectra and their labels onto new 
spaces such that the covariance between the resultant matrices is maximal [37]. 
While the PLS loadings (unlike PCA loadings) are not easily interpretable, PLS-
DA is particularly suited for spectral datasets with fewer instances than variables. 
However, under specific circumstances, the method has been shown to have 
similar performance as LDA and Euclidean distance to centroids, along with the 
associated disadvantages [37]. 
Non-linear supervised classification: While the linear classification methods are 
suitable for linearly separable datasets, a significant proportion of tasks 
encountered in the diagnosis of closely related and heterogenous pathological 
states using Raman spectroscopy demand robust modeling of non-linear class 
boundaries. To tackle such problems, support vector machines (SVM) have been 
frequently used in conjunction with appropriate kernel functions. SVM are used to 
identify a maximum margin class-separating hyperplane in the training dataset (Fig. 
1.3). The use of appropriate kernel function allows building classification models 
for datasets that are not linearly separable by projecting them into high dimensional 
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space and finding a suitable hyperplane in the transformed space. However, the 
obtained model, weights and parameters are not easily interpretable. Various 
implementations of SVM have been proposed in the literature along with a variety 
of optimization algorithms for classification in single, binary and multi-class settings. 
Appropriate selection of parameters for a given implementation is very critical to 
obtain high classification accuracy and avoid overfitting. LIBSVM, a very popular 
SVM library provides a powerful platform for implementing SVM and parameter 




Figure 1.3: Multivariate data analysis. (A) Schematic representation of support 
vector machines showing identification of optical hyperplane for maximum margin 
between the classes. (B) Schematic representation of an artificial neural network 
with a single hidden layer showing the flow of data from input to output layer. 
Adapted from ref. 34 (Licensed under CC BY SA 4.0).  
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Artificial neural networks (ANN) is another powerful tool that has been 
widely used for modeling non-linear class boundaries in Raman spectroscopy 
datasets. The ANN classification, motivated by biological neural networks, involves 
modeling the relationship between training spectral dataset and class labels by 
learning the weights of inputs at each of the multiple transformations incorporated 
as a network of hidden layers between input and output layers (Fig. 1.3). Various 
methods such as backpropagation that iteratively learns and adjusts the weights 
of the network by minimizing the training error have made ANN fast and efficient. 
Due to the ability to model a wide range of complex functions, ANN with a large 
number of hidden layers can result in overfitting of the data for small datasets if 
caution is not exercised [39]. Additionally, the hidden layers serve as a black box 
and fail to identify the key contributors of the differences between classes of 
interest (e.g. benign vs. malignant cancers). However, the hardware developments 
enabling faster acquisition of large Raman datasets and emerging interest in deep 
learning are expected to make ANN and its variants more attractive. 
Towards big data analysis: Traditionally, Raman spectroscopic datasets have 
been relatively small due to the low throughput and lack of automation in spectral 
data collection. However, recent developments in automation and integration of 
Raman spectroscopy and its faster variants that utilize surface enhancement 
(SERS) and non-linear processes (CARS and SRS) with advanced microscopes 
have enabled collection of large Raman datasets from a variety of biological media 
such as cells, tissues, and body fluids. The successful acquisition of large spectral 
datasets using these technologies, especially 2D and 3D Raman maps will enable 
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researchers to translate the recent success in image classification using deep 
learning frameworks. The standardization of data acquisition protocols for spectral 
acquisition of cells and tissues for each class of diseases will allow us to build, 
share and continuously expand the Raman datasets to capture inter-patient 
heterogeneity, train robust deep learning models and translate other emerging big 
data tools. 
1.4 Variants of Raman spectroscopy 
In addition to spontaneous Raman spectroscopy, several variants have been 
demonstrated for medical applications where attributes such as higher sensitivity, 
depth selectivity, specific targeting and resonance enhancement are desirable. In 
this section, some prominent variants of Raman spectroscopy with potential for 
clinical translation will be briefly discussed. 
1.4.1 Surface enhanced Raman spectroscopy (SERS) 
A significant enhancement of electromagnetic field is achieved close to the metal 
surfaces due to excitation of localized surface plasmons. Surface enhanced 
Raman spectroscopy exploits this phenomenon for selective enhancement of 
Raman signal from molecules adsorbed on the metal surfaces by up to 11 orders 
of magnitude [40]. Metallic nanostructures made up of gold and silver have been 
used for SERS applications owing to their strong surface plasmon resonance in 
visible and NIR regions, where most Raman laser lines lie. Various nanostructures 
such as spheres, cubes, stars, rods and wires have been extensively studied for 
obtaining maximal SERS enhancement for a variety of applications in biology and 
medicine. Most studies utilize SERS enhancement to boost the detection 
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sensitivity of low concentration analytes in one of the following two configurations. 
The label-free SERS or direct detection involves bringing the analyte close to the 
nanostructures for maximal enhancement of their intrinsic Raman signatures. This 
configuration has been used for studying biofluids, tissues and cells for 
identification of disease biomarkers. While untargeted enhancement of all the 
constituents of biological media improves the sensitivity of detection (and reduction 
in laser exposure), it fails to exploit known markers for increased specificity via 
targeting. Therefore, targeted applications, also known as indirect detection, 
employ nanoprobes composed of Raman active reporter molecules tightly packed 
with the metal nanostructures. The surface of such nanoprobes can be modified 
to selectively bind with the analyte of interest for its indirect quantification by 
measuring the signal from the Raman reporter molecules. However, the 
widespread use of SERS tags for in vivo applications is impeded by concerns 
about toxicity of the used nanoparticles. Several constructs involving the use of a 
thin protective shell gold, silica or polymers (e.g. polyethylene glycol) have been 
proposed to improve the biocompatibility of SERS nanoparticles. 
1.4.2 Resonance Raman spectroscopy  
The weak Raman signals can be significantly enhanced when the excitation 
frequency is resonant with one of the electronic absorption bands [41]. Such 
enhancement enables preferential enhancement of vibrational modes associated 
with chromophores without interference from other components of complex 
mixtures in which they are present. For example, such resonant enhancement 
allows the study of specific parts of large protein molecules, e.g. the heme region 
20 
 
in myoglobin, without affecting the signal from other regions. However, since most 
lasers currently used in Raman spectroscopy are not easily tunable, only a few 
modes whose absorption bands match the wavelengths of the available laser lines 
can be conveniently probed. Additionally, due to the use of lasers in the UV and 
visible regions and absorption by the chromophores of interest, the resonance 
Raman spectra are almost always associated with a strong fluorescence 
background. Fortunately, strategies such as using shorter wavelengths into the 
deep-UV region and time-gating for selectively rejecting the fluorescent scattered 
photons have shown promise for alleviating the strong fluorescence background 
and associated shot noise in resonance Raman measurements. A range of 
applications focused on the spectroscopic measurement study of molecules such 
as nucleic acids, proteins and metalloproteins in their native states as well as in 
complex biological matrices, have utilized resonance Raman spectroscopy. 
1.4.3 Spatially offset Raman spectroscopy (SORS)  
The poor penetration depth provided by visible and NIR lasers used for Raman 
spectroscopy prevents interrogation of deeper layers of tissue. To obtain Raman 
signal from the deeper regions, spatially offset Raman spectroscopy employing a 
configuration that involves spatial separation of the illumination source from the 
detection zone has been used (Fig. 1.4) [28]. Such illumination-collection 
separation provides a route for preferential retrieval of spectra from deeper layers 
of diffusely scattering media by combining measurements at multiple offsets and 
multivariate data analysis methods. Various source-detector separation 
configurations involving single or multiple zones of illumination as well as detection 
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using fiber optics have been demonstrated for biomedical and pharmaceutical 
applications. One such configuration featuring central collection zone and a 
spatially offset illumination ring (using axicons), called inverse SORS is particularly 
suited for clinical applications due to the lower laser power density and multiple 
spatial offsets achieved by the use of ring illumination. While SORS has shown 
promise for applications such as breast cancer detection, tomographic imaging 
and blood glucose detection, its implementation is particularly challenging for 
highly absorbent and fluorescent samples. 
 
 
Figure 1.4: Schematic representation of the spatially offset Raman 
spectroscopy (SORS) principle in comparison to spontaneous Raman 
spectroscopy. R, L and Δs denote backscattered, laser beam and spatial offset, 




1.4.4 Non-linear Raman spectroscopy 
The non-linear techniques, particularly coherent anti-Stokes Raman spectroscopy 
(CARS) and stimulated Raman spectroscopy (SRS), have emerged as attractive 
variants to address low yield and strong fluorescence background encountered in 
biological species. Both the methods have been successfully integrated in 
microscopes for investigation of cells and tissues. In CARS, a coherent anti-Stokes 
signal is generated by the interaction of pump, Stokes and probe frequencies in a 
four-wave mixing process as shown in Fig. 1.5 [42]. The key advantages provided 
by CARS over spontaneous Raman include the suppression of fluorescence, 
higher yield due to the coherent laser-like output, and the dependence of spectral 
resolution only on the excitation laser width. However, non-resonant background 
signal from the matrix can limit the specificity of the technique by obscuring the 
CARS signal at low concentrations. CARS microscopy has been utilized for 
visualization of lipids and other biomolecules in live cells by appropriately tuning 
the difference frequency between pump and stokes beams to match specific 
vibrational bands (e.g. C-H band in lipids) with high 3D spatial resolution. On the 
other hand, SRS microscopy uses pump and Stokes laser beams such that their 
frequency difference matches specific molecular vibrational frequency of interest 
to achieve significant enhancement of the associated Raman signal due to 
stimulated excitation without non-resonant background (Fig. 1.5) [42-45]. The 
linear dependence of SRS signal with the concentration of analyte makes it 
suitable for direct quantification of individual components in multicomponent 
mixtures. Emerging medical applications of SRS microscopy have used the higher 
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sensitivity and specificity to achieve fast mapping of cells and tissues (Fig. 1.6) 
[43]. While, the inability to probe multiple Raman bands simultaneously used to be 
a major drawback of SRS microscopy, recent studies have shown multiplexing 
using a variety of methods [44, 45]. 
 
 
Figure 1.5: Jablonski diagrams. Jablonski diagrams for (A) CARS and (B) SRS 
processes are shown. Reproduced from ref. 42 (Licensed under CC BY SA 3.0). 
 
 
1.5 Medical applications of Raman spectroscopy 
In recent years, the excellent sensitivity and chemical specificity offered by Raman 
spectroscopy and its variants have been exploited for a variety of medical 
applications through clinical and pre-clinical studies. In this section, we will discuss 








Figure 1.6: SRS microscopy of cells. Label free stimulated Raman scattering 
microscopy of fixed squamous cell carcinoma cells acquired at (A) 2953 
cm−1 (CH3), (B) 2850 cm−1 (CH2, lipid), (C) 1655 cm−1 (C O, amide-I), and (D) 
1700 cm−1 (cellular silent region). Scale bars are 5 μm. Reproduced from ref. 43 




1.5.1 Applications in cancer 
Clinical Diagnostics: Breast cancer, one of the most common forms of cancer in 
women, has been extensively studied using Raman spectroscopy and its variants. 
Early investigations of breast cancer using Raman spectroscopy exploited high 
Raman scattering cross-section exhibited by mammary microcalcifications, which 
are frequently used to assess breast disease. The benign and malignant breast 
cancers have been accurately identified based on differences in Raman signatures 
of type I (composed of calcium hydroxyapatite) and type II (composed of calcium 
hydroxyapatite with carbonate substitution) mammary microcalcifications, 
respectively [46]. Raman spectroscopy has also been employed to discern a 
variety of breast lesions ranging from benign fibroadenoma to invasive ductal 
hyperplasia in samples that do not present microcalcifications, with accuracies 
upwards of 85% for the diseased classes [47]. The enhancement of surface 
Raman signal using silica-shell isolated nanoparticles for the same samples 
provided further improvement in accuracy (> 90%) for most classes. The use of 
multivariate data analysis tools like PCA provides important insights into the 
disease-specific compositional changes in the tumor microenvironment. Using 
controlled tissue constructs composed of calcium salts (hydroxyapatite, oxalate 
and carbonate-substituted hydroxyapatite) embedded in chicken tissue at varying 
depths, the efficacy of detecting microcalcifications from deeper subsurface 
regions using SORS was demonstrated for depths ranging from 2 mm to 10 mm 
[48]. SERS has been explored extensively for studying breast cancer cells and 
biofluids from patients by incorporating a variety of nanoparticles. A majority of 
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SERS studies for breast cancer cells have been conducted for targeted 
quantification of cell surface markers such as HER2 and EGFR, that are 
differentially expressed in cancer cells, via nanoprobes modified with relevant 
antibodies for preferential binding to the antigens expressed on their membranes. 
The SERS nanoprobes used in these studies can be readily adapted for targeted 
identification of cancer cells from other organs if appropriate biomarkers are known. 
In vivo targeting of cancer cells in tumor xenografts pegylated gold nanoparticles 
containing organic Raman reporter molecules has been demonstrated by targeting 
EGFR using single-chain variable fragment (ScFv)-antibody conjugation [49]. 
Among other accessible cancers, the diagnosis of skin cancer has also 
been an important application of Raman spectroscopy due to high incidence rates 
and sampling errors encountered during biopsy for diagnosis. Several groups have 
studied benign and malignant skin cancers both in vitro and in vivo for developing 
diagnostic algorithms for real-time noninvasive detection. In a comprehensive 
Raman spectroscopy study incorporating 453 patients presenting various types of 
melanomas, carcinomas, keratoses and nevi, principal component general 
discriminant analysis and partial least squares have been used for three different 
diagnostic classification tasks – skin cancer and precancers vs. benign lesions, 
melanomas from nonmelanoma lesions, and melanomas from seborrheic 
keratoses with area under the curve (AUC) values of over 0.82 for each [50]. 
Several applications in cervical cancer screening have been demonstrated based 
on Raman spectroscopy to detect cytopathological changes, HPV infection status 
(a key risk factor) as well as differences in protein, lipids and nucleic acid content 
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between benign and malignant lesions [51]. Early in vivo study using fiber optic 
probes revealed an association between an increase in collagen, phospholipid and 
DNA signatures and progression of tissue from normal to high-grade squamous 
dysplasia [52]. 
The in vivo application of Raman spectroscopy for diagnosis of inaccessible 
cancers requires seamless integration of the fiber optic probes with endoscopy 
workflow. Motivated by ex vivo studies that demonstrated the potential for use of 
fiber-optic Raman probes for in vivo diagnosis, studies have focused on 
endoscopic detection of cancers and other abnormalities in esophagus, stomach 
and colon. The LDA classification model developed using in vivo esophageal 
Raman measurements obtained from 27 patients during clinical endoscopic 
examination of esophagus and biomolecular modeling yielded sensitivity and 
specificity of 97% and 95.2%, respectively for the diagnosis of esophageal cancer 
[53]. The biomolecular modeling revealed that neoplasia was associated with a 
decrease in actin, collagen, lipids and glycogen as well as an increase in DNA and 
histones concentration. In vivo studies in rats have showed the feasibility of using 
topically applied antibody-conjugated SERS nanoparticles for sensitive detection 
and quantification of cell surface markers of esophageal cancer [54]. Translation 
of such protocols to human patients are expected to enable identification of 
hormone receptor status along with disease diagnosis. In vivo Raman endoscopic 
examination of gastric tissue in 305 patients enabled the construction of a spectral 
database for developing a diagnostic algorithm based on PLS-DA for in-line 
detection of gastric cancer in independent patient samples with a predictive 
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accuracy of ca. 80% [55]. In the colon, various polyps and adenocarcinomas have 
been studied both in vivo and ex vivo using fiber-optic Raman probes that are 
compatible with conventional colonoscopes [56]. Additional advancements such 
as utilizing high wavenumber spectral regions for diagnosis have hinted at 
improving the capabilities of Raman spectroscopy in endoscopic applications. 
Intra-operative surgical guidance: The lack of complex sample preparation 
steps and minimal perturbation to the tissue due to NIR lasers used in Raman 
spectroscopy makes it an attractive tool for real-time assessment of margins during 
tissue conserving surgeries. One of the first studies in this direction was conducted 
in vivo in 9 patients undergoing partial mastectomy breast surgery, where 
previously developed classification algorithms have yielded accurate classification 
of malignant among normal and benign tissues [57]. However, the residual 
subsurface tumors under surgical margins can result in recurrence of cancer. To 
circumvent this challenge, spatially offset Raman probes have been developed 
and validated for successful classification of positive and negative margins in 
frozen-thawed breast surgical samples ex vivo [58]. Another ex vivo study using 
breast surgical samples showed the potential for accelerating acquisition of Raman 
micro-spectroscopy data by employing autofluorescence imaging for selective 
sampling of spatial locations [59, 60]. Such multimodal approaches can 
significantly reduce the Raman data acquisition time and provide higher sensitivity 
for real-time detection of tumor margins during surgery. In vivo application of 
Raman spectroscopy in 38 bladder cancer patients during transurethral resection, 
sensitivity and specificity over 75% have been achieved using PCA/LDA 
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classification analysis [61]. In brain cancer, another organ where conserving tissue 
during surgery is critical for retaining key functions and memory, a recent study 
employed 17 patients undergoing resection of grade 2 to 4 gliomas for in vivo 
identification of cancer margins composed of high and low density tumor cells 




Figure 1.7: SERS imaging of tissues markers. (A) SERS imaging of two HER2-
positive specimens containing both tumor and normal tissue regions and two 
HER2-negative specimens (one tumor and one normal tissue) by topical 
administration of a nanoparticle (NP) mixture of HER2-NPs and isotype-NPs for 
targeted identification of regions overexpressing HER2 receptor based on the ratio 
of bound NPs. (B) Immunohistochemical staining of the same samples with an 
anti-HER2 antibody. Unlabeled scale bars represent 2 mm. Adapted from ref. 63 
(Licensed under CC BY 4.0). 
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Some early studies have also shown the feasibility of using SERS imaging 
of resected samples for intra-operative margin assessment and surgical guidance 
in clinic. The in vitro success in quantifying cell surface receptors that are 
overexpressed in cancer using targeted SERS nanoparticles has motivated similar 
studies for identification of margins by topical application of nanoparticles on 
surface of freshly excised tissue specimen. In a recent study, topical application of 
a multiplexed cocktail of SERS nanoparticles has resulted in quantification of 
molecular phenotype in terms of receptor status. Using a mixture of SERS 
nanoparticles functionalized with HER2 and isotype antibodies, tumor margins 
have been determined based on HER2 status in freshly excised tissue samples 
obtained at breast cancer lumpectomy (Fig. 1.7) [63]. Another similar study 
employed a similar approach for simultaneous quantification of HER2, ER, EGFR 
and CD44 in 57 clinical sample for detection of breast carcinoma with sensitivity 
and specificity of 89.3% and 92.1%, respectively [64]. A study targeted at 
understanding the biodistribution of ingested SERS nanoparticles in the body has 
revealed their potential to be used in vivo for topical application in oral cavity and 
GI tract without worrying about permeation into the blood stream or accumulation 
in vital organs [65]. 
Evaluation of metastatic disease: While Raman spectroscopy has been 
extensively used for establishing feasibility of clinical translation in cancer 
diagnostics, emerging studies have also focused on understanding the molecular 
mechanisms driving key characteristics of cancer and its metastatic progression. 
In mice harboring metastatic brain tumors induced by murine melanoma cells, 
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Raman spectroscopy using a fiber-optic probe enabled the detection of cortical 
and subcortical tumor cell aggregates in the brain based on spectral features 
stemming from proteins, lipids, blood, water, bone, and melanin [66]. Similar mice 
studies of prostate cancer metastasis to bone using Raman spectroscopy revealed 
compositional changes in the bone such as an increase in carbonate substitution 
in hydroxyapatite and a decrease in collagen mineralization and mineral 
crystallinity (often correlated with physical properties of bone), that were 
independent of architectural alterations determined using microCT [67]. A recent 
study by our group showed that Raman spectroscopy was able to identify early 
biochemical changes in the composition of bones of mice bearing breast tumor 
xenografts, before the emergence of morphological indicators discernible by 
radiographic imaging [68]. The metastasis of breast cancer cells to lymphatic 
system in patients is routinely determined by sampling axillary lymph nodes. The 
Raman spectroscopic evaluation of 38 axillary lymph nodes (25 negative and 13 
positive for metastatic spread) obtained from 20 patients undergoing breast cancer 
surgery were used to create a leave one node out cross validation routine based 
on PC-LDA that yielded sensitivity and specificity over 90% for prediction of normal 
and metastatic lymph nodes [69].  
A large number of studies have also focused on employing Raman 
spectroscopy to study metastasis at cellular level by employing spontaneous 
Raman as well as labeled and label-free SERS using a variety of nanoparticles. A 
recent study established the feasibility of employing label-free Raman 
spectroscopy for classification of isogenic cell lines that show organotropism to 
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brain, liver, lung and spine [70]. The findings were supported by metabolomic 
analyses that showed distinctions in the cell lines based on organotropism. 
However, identification of rare cells in complex matrices often requires the use of 
labeled SERS for obtaining the required sensitivity. A study aimed at detection of 
circulating tumor cells (CTCs) in human peripheral blood derived from patients with 
different stages of head and neck squamous cell carcinoma accomplished it by 
using EGF-conjugated SERS nanoparticles for targeting epidermal growth factor 
expressed by the CTCs [71]. They showed that the SERS intensity of the samples 
correlated with the number of CTCs present per mL of the sample. These studies 
show that Raman spectroscopy and its variants are suitably poised to tackling 
advanced challenges in cancer such as determination of metastatic risk and 
organotropism. 
1.5.2 Applications beyond cancer 
The medical applications of Raman spectroscopy are not limited to 
oncology. A significant amount of work has also focused on key areas of human 
health such as management of chronic diseases, diagnosis of infectious diseases, 
and prediction of risk of acute illness. Non-invasive glucose detection for diabetes 
monitoring has been one of the long-standing goals in Raman spectroscopy. 
Several studies have made progress towards accomplishing this goal by 
addressing several challenges such as sample-to-sample variability, 
autofluorescence due to endogenous chromophores, tissue turbidity, physiological 
lag between blood and interstitial fluid glucose levels, and non-linear spectra-
concentration relationship (Fig. 1.8) [72]. For instance, turbidity correction by 
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combining diffuse reflectance and Raman spectroscopy measurements under the 
assumption that the effects of turbidity manifest similarly in both the modalities 
yielded significant improvement in glucose concentration prediction. Similarly, the 
inaccuracies induced in the spectra-concentration calibration models due to the 
difference in glucose concentration between blood and interstitial fluid 
compartments have been mitigated by modeling the physiological glucose 
dynamics using mass transfer principles. 
 
Figure 1.8: Non-invasive glucose monitoring using Raman spectroscopy. (A) 
Simulations of effects of tissue turbidity on sampling volume is shown for different 
scattering coefficients. (B) Schematic showing the similarity of photon-tissue 
interactions for diffusely reflected and Raman scattered light of same frequency. 
(C) Illustration of glucose diffusion between the blood and interstitial fluid (ISF) as 
well as cellular uptake that cause inaccuracies in calibration models built to predict 
blood glucose levels based on Raman measurements of ISF glucose. (D) The 
resultant lag between the glucose in blood and ISF compartments leads to 
differences in measurements during rapid changes (rise/fall) in glucose 









Figure 1.9: Identification of fungal growth zones using Raman spectroscopy.  Radial 
visualization PC score plots derived from (A) spontaneous Raman and (B) label-free 
SERS spectra acquired from center and edge of the P. indica fungal cultures are shown. 
Reproduced with permission from ref. 74. Copyright 2017 Wiley‐VCH Verlag GmbH & Co. 
KGaA. 
 
The diagnosis of infectious disease agents is another important area where 
the ability of Raman spectroscopy to provide rapid diagnosis is immensely valuable. 
One of the early studies utilizing NIR confocal Raman micro-spectroscopy of 
common microorganisms on solid culture medium showed test dataset 
classification accuracy upwards of 80% for the combined spectral dataset 
composed of multi-day measurements from five types of bacterial microcolonies 
using a combination of PCA and LDA [73]. More recently, the study of different 
growth zones of fungal cultures by us using a combination of light sheet 
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microscopy and Raman spectroscopy revealed that the biochemical basis of 
morphological differences across the growth zones were sufficient for accurate 
classification of the growth zones using PLS-DA [74]. By dispersing SERS 
nanoparticles on the surface of fungal culture further improved the classification 
accuracy without specific targeting (Fig. 1.9). However, the ability to identify 
microorganisms in complex matrices such as blood and other biofluids is critical 
for field translation. Direct identification of predominant bacterial species causing 
urinary tract infections (UTI) in urine samples collected from 10 patients was 
demonstrated by combining Raman micro-spectroscopy and SVM model trained 
on a spectral database built using 11 important UTI bacterial species, without the 
need of a cell culture step before acquisition of Raman spectra [75]. Similarly, 
Raman spectroscopy and PCA has been used to monitor changes in erythrocytes 
and plasma associated with progression of malaria by exploiting the resonant 
enhancement of hemoglobin and hemozoin [76]. Several other pathologies such 
as coronary atherosclerosis, middle ear diseases, osteoarthritis and dental 
abnormalities have been explored using Raman spectroscopy and its variants in 
conjunction with multivariate data analysis techniques [77-81]. For instance, 
successful classification of infracted and non-infracted tissue regions in myocardial 
in surgically excised ventricular myocardium has been recently shown for label-





Figure 1.10: Detection of myocardial infarction using Raman spectroscopy. 
(A) A representative H&E-stained image showing the boundary between the 
infarcted (labeled I) and non-infracted (labeled II) regions of the heart tissue 
excised from human patients is shown. Representative mean Raman spectra 
belonging to (B) non-infarcted myocardium and (C) infarcted myocardium regions 
in the samples from each patient is shown. Scale bar represents 1 mm. 
Reproduced from ref. 82 (Licensed under CC BY SA 4.0). 
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1.6 Thesis outline 
This dissertation aims to highlight our recent work that leverages the exquisite 
molecular specificity of Raman spectroscopy to study cancer progression and its 
response to therapy. Following the brief introduction to medical applications of 
Raman spectroscopy that is laid out in the present chapter, I first focus on our 
investigations into the utility and genetic basis of mammary microcalcifications as 
markers of primary breast cancer diagnosis. In the later chapters, I discuss our 
studies focused on the spectral characterization of pre-metastatic niches and 
response to radiation therapy, applications that go beyond primary disease 
diagnostics. The thesis is organized as follows:  
In Chapter 2, we demonstrate the use of Au@SiO2 shell-isolated 
nanoparticle-enhanced Raman spectroscopy (SHINERS) for assessment of 
microcalcifications and distinguishing between normal breast tissues, 
fibroadenoma, atypical ductal hyperplasia, ductal carcinoma in situ (DCIS), and 
invasive ductal carcinoma (IDC) in human patient samples. We assess the effect 
of SHINERS signal enhancement on the accuracy of classification routine used for 
the identification of breast lesions with and without microcalcifications. By 
comparing the classification accuracies obtained in lesions with and without 
microcalcification using both SHINERS and traditional spontaneous Raman 
spectroscopy, we also examine the magnitude of relative improvement provided 
by the pursuit of mammary microcalcifications for diagnosis of breast cancer in 
current clinical practice. 
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In Chapter 3, we investigate the genetic basis of breast cancer 
microcalcifications and elucidate their role in metastasis. Guided by the gene 
expression analysis of metastatic and non-metastatic breast cancer cell lines, we 
show that among the genes previously implicated in the formation of 
microcalcifications, Osteopontin (OPN) varies the most between the two groups. 
We study the direct effect of OPN on the osteogenic cocktail-induced 
microcalcification formation and cell migration via stable shRNA silencing of OPN 
in MDA-MB-231 cells. Furthermore, we also compare the relative levels of OPN 
mRNA in parental MDA-MB-231 cells with those derived from circulation (CTC) 
and lungs (LM) of mice implanted with the parental cells, to verify correlation of 
OPN with cell migration. 
In Chapter 4, we turn our attention to the metastatic disease. Here, we test 
the ability of label-free Raman spectroscopy to detect early changes in the future 
secondary sites of metastatic disease in advance of tumor cell arrival from the 
growing primary tumor. We use high metastatic MDA-MB-231 and low metastatic 
MCF-7 cells to grow orthotopic breast cancer xenograft for spontaneous 
dissemination from the mammary fat pad and potentially metastasize to the lungs. 
We map the lungs of the mice excised during the pre-metastatic phase and acquire 
spectral dataset for multivariate data analysis and identification of markers 
indicative of subtle biomolecular changes in the lung microenvironment as a result 
of the formation of pre-metastatic niches. We use histopathology and gene 
expression analysis to support the Raman features identified in the study. 
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In Chapter 5, we explore the possibility of monitoring response to radiation 
therapy at clinically relevant dosages and prospective prediction of responders 
using Raman spectroscopy. Here, we employ an isogenic matched model of 
radiation resistance consisting of A549 lung cancer cells and their resistant variant 
rA549 cells to grow tumors in mice to reliably study the differences due to 
sensitivity to radiation therapy. We also use tumors derived from sensitive and 
resistant head and neck cancer cells to delineate model-specific markers of 
response and sensitivity. Using multivariate curve resolution alternating least 
squares (MCR-ALS) and support vector machine (SVM) classification, we 
determine the putative markers of radiation response and sensitivity and build 
models for prospective prediction. 
Finally, in Chapter 6, I summarize the key findings of the abovementioned 
studies and discuss some future research directions that can build on the recent 
developments in the area to facilitate the rapid translation of this promising 
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Pursuing shell-isolated nanoparticle-enhanced Raman 
spectroscopy (SHINERS) for concomitant detection of breast 
lesions and microcalcifications 
  
Although tissue staining followed by morphologic identification remains the gold 
standard for diagnosis of most cancers, such determinations relying solely on 
morphology are often hampered by inter- and intra-observer variability. Vibrational 
spectroscopic techniques, in contrast, offer objective markers for diagnoses and 
can afford disease detection prior to alterations in cellular and extracellular 
architecture by furnishing a rapid “omics”-like view of the biochemical status of the 
probed specimen. Here, we report a classification approach to concomitantly 
detect microcalcification status and local pathological state in breast tissue, 
featuring a combination of vibrational spectroscopy that focuses on the tumor and 
its microenvironment, and multivariate data analysis of spectral markers reflecting 
molecular expression.  
We employ the unprecedented sensitivity and exquisite molecular 
specificity offered by Au@SiO2 shell-isolated nanoparticle-enhanced Raman 
spectroscopy (SHINERS) to probe the presence of calcified deposits and 
 
 This chapter is a reprint of the peer-reviewed publication: Zheng C*, Shao W*, Paidi SK, Han B, 
Fu T, Wu D, Bi L, Xu W, Fan Z, Barman I. “Pursuing shell-isolated nanoparticle-enhanced Raman 
spectroscopy (SHINERS) for concomitant detection of breast lesions and microcalcifications”, 
Nanoscale, 7, 16960-8, 2015. (* denotes equal contribution) 
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distinguish between normal breast tissues, fibroadenoma, atypical ductal 
hyperplasia, ductal carcinoma in situ (DCIS), and invasive ductal carcinoma (IDC). 
By correlating the spectra with the corresponding histologic assessment, we 
developed partial least squares-discriminant analysis derived decision algorithm 
that provides excellent diagnostic power in the fresh frozen sections (overall 
accuracy of 99.4% and 93.6% using SHINs for breast lesions with and without 
microcalcifications, respectively). The performance of this decision algorithm is 
competitive with or supersedes that of analogous algorithms employing 
spontaneous Raman spectroscopy while enabling facile detection due to the 
considerably higher intensity of SHINERS. Our results pave the way for rapid 
tissue spectral pathology measurements using SHINERS that can offer a novel 
stain-free route to accurate and economical diagnoses without human 
interpretation. 
2.1 Introduction 
Examination of stained histology slides and the corresponding recognition of 
morphologic features remains the gold standard for definitive diagnosis and 
staging of most cancerous lesions. The decision-making relies extensively on a 
pathologist’s recognition of cell types and their morphologic patterns within the 
stained tissues. Although early detection and useful patient stratification impact the 
likelihood of cancer-free survival, manual morphological determinations involve 
considerable diagnostic uncertainty [1, 2] and do not elucidate the essential 
biochemical pathways that lead to the specific pathology. Moreover, such 
examination is time-consuming and expensive. While immunohistochemical 
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approaches offer limited molecular detection, significant hurdles still remain in 
employing them for quantitative, automated pathology [3].  
In this milieu, considerable attention has been focused on the incorporation of 
vibrational spectroscopic methods, as they directly offer non-perturbing molecular 
descriptors. Raman spectroscopy, for example, provides objective spectral 
markers for diagnosis of disease and may permit disease detection prior to 
morphologic manifestation [4]. Studies by us and others [5-14] have sought to 
exploit this method - due to its wealth of molecular information [15, 16] and lack of 
sample preparation requirements - in differentiating breast pathology and detecting 
the presence of microcalcifications, an important mammographic marker of breast 
lesions. While spontaneous Raman spectroscopy affords sub-cellular signal 
localization and provides an ideal in vivo characterization tool, its inherently weak 
signals have impeded its application for extensive tissue analysis.  
Surface-enhanced Raman scattering (SERS), which was first observed in 
the 1970s on electrochemically roughened silver electrodes [17, 18], has alleviated 
this drawback with reported biomolecular detection limits beyond immunoassay 
sensitivities [19]. As a consequence, SERS has attracted considerable interest as 
an ultrasensitive and highly specific tool for non-destructive and real-time 
diagnosis of diseases [15, 20-28]. However, two problems still hinder the 
translation of SERS for biomedical applications, namely unsatisfactory substrate 
generality and poor measurement reproducibility [29, 30]. To overcome these 
drawbacks, shell-isolated nanoparticle-enhanced Raman spectroscopy 
(SHINERS), featuring nanoparticles with Au core coated by an ultrathin shell 
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(thickness from 2-20 nm) of silica or alumina, was proposed by Tian and co-
workers at Xiamen University [31] While the gold core of the Au@SiO2 shell-
isolated nanoparticles (SHINs) allows obvious SERS enhancement, the shell is 
used to protect the gold core from degradation of the minutely fabricated 
nanostructures as well as preclude the interaction of the bare gold nanoparticles 
with the probed adsorbates. By virtue of these advantages, SHINERS has been 
gainfully employed in investigations of live cells [32] and, recently by us, in 
carcinoma studies using a ratiometric approach [33]. 
Using breast cancer as the paradigm, we report here an approach to 
concomitantly diagnose microcalcification status and local pathological state 
featuring SHINERS and multivariate data analysis of spectral markers reflecting 
molecular expression. In this article, we seek to exploit the heightened sensitivity 
and intrinsic specificity offered by the Au@SiO2 shell-isolated nanoparticles in 
elucidating the biochemical content of fresh frozen specimen and, thus, in 
differentiating between normal breast tissue, fibroadenoma, atypical ductal 
hyperplasia, ductal carcinoma in situ, and invasive ductal carcinoma. By 
correlating the spectra with the histologic evaluation, our partial least squares - 
discriminant analysis derived decision algorithms show excellent diagnostic power 
(overall accuracy of 99.4% and 93.6% using SHINs for breast lesions with and 
without microcalcifications, respectively). The performance of this decision 
algorithm is competitive with or supersedes that of analogous algorithms 
developed using spontaneous Raman spectra while offering facile detection owing 
to the considerably higher intensity of SHINERS spectra. Notably, to the best of 
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our knowledge, this is the first SHINERS effort that comprehensively assays 
microcalcifications and tissues of all key pathophysiological conditions. Taken 
together with the substantially higher spectral intensities for the SHINERS data in 
relation to that for the spontaneous Raman spectra, our findings open the door for 
clinical translation of SHINERS as a label-free route to accurate pathological 
diagnoses without human interpretation. 
2.2 Materials and Methods 
2.2.1 Human subjects and tissue preparation  
Fresh breast tissue was collected from 72 patients who underwent surgical 
resection or vacuum assisted (Mammotome) biopsy at the Department of Breast 
Surgery, the First Hospital of Jilin University. Consent to participate in this study 
was obtained from every patient and the project and methodology were approved 
by the Ethics Committee of Jilin University. After operating, the samples were 
immediately frozen at -20 to -25 oC and two contiguous sections (6 µm thickness) 
were cut from each specimen using a freezing microtome (LEICA-CM3050S, 
Germany) in the Pathology Department, the First Hospital of Jilin University. For 
each tissue, one of the two adjacent sections were stained with haematoxylin and 
eosin (H&E) for routine histopathological analysis by three experienced breast 
pathologists. The other section was used for acquiring spectra from the diseased 
regions (identified by H&E staining of the other section) by preserving it in liquid 
nitrogen. Prior to analysis, the frozen section was thawed at 22 oC for 10 minutes 
and multiple spectra were collected from each tissue. 
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2.2.2 Instrumentation and data acquisition  
A confocal Raman system (LabRAM ARAMIS, Horiba Jobin Yvon, Edison, NJ, 
USA) with a ~0.7 μm spatial resolution, and a 5 mW, 633nm HeNe laser as 
excitation source was used for the collection of Raman spectra. The detection of 
Raman signal was carried out with a Synapse Thermoelectric cooled charge-
coupled device (CCD) camera (Horiba Jobin Yvon, Edison, NJ, USA). Raman 
scattered light was collected with a 50x microscope objective lens (0.50 NA, 
LMPLFLN, Olympus, Japan) that was also used for focusing the excitation laser 
light. The laser beam focused on the tissue formed a spot of 1.5 µm diameter. A 
4-notch filter (Horiba Jobin Yvon, Edison, NJ, USA) was used to block strong 
Rayleigh-scattered light. Extended scan spectra with a spectral range of 600-1800 
cm−1 were acquired using an integration time of 60s and 3 accumulations. The 
Raman shift axis was calibrated using characteristic vibration bands recorded from 
silicon wafer. These settings were kept constant for all the spectral measurements 
to enable direct comparison of spectral sensitivity and specificity, especially 
between spontaneous Raman and SHINERS datasets. 
Locations of lesions and other possible features of interest were determined from 
the H&E sections and the corresponding sites on its frozen contiguous sections 
were probed using the Raman system. About fifteen to twenty spectra were 
collected from different locations for each sample to ensure representative 
sampling and incorporate spot-to-spot variability in the recorded signals. After 
obtaining spontaneous Raman spectra, SHINs were added to the surface of frozen 
sections and the respective SERS spectra were recorded from the same spots. 
58 
 
SHINs having an average Au core diameter of 55 nm and covered by 2 nm silica 
shells were acquired from Professor Tian’s group for use in this study. On each 
tissue section 10 μL of 100 nM concentrated SHINs solution was added uniformly 
prior to collecting the spectra. Figure 2.1 shows a representative TEM image of 
the SHINs used for our study. 
 
 
Figure 2.1: Representative TEM image of Au@SiO2 shell-isolated 
nanoparticles (SHINs). 
 
2.2.3 Spectral data analysis 
The spectra were subjected to baseline correction by fitting and subtracting a third-
order polynomial by NGSLabSpec software (Horiba Jobin Yvon, Edison, NJ, USA) 
and were subsequently smoothed using a 15-point averaging algorithm. These 
corrected spectra were used to determine the peaks characteristic of the class the 
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spectra belong to while the intensity-normalized spectra were used in the 
remaining data analysis. The latter were subjected to principal component analysis 
(PCA), a widely used data exploration method, to capture the (subtle) spectral 
variances in a set of abstract orthogonal axes. For every spectrum belonging to a 
different pathological class, PC scores were plotted using Radviz and VizRank, 
radial visualization modules in Orange data mining software [34]. The nonlinear 
multidimensional radial visualization algorithm, RadViz, maps n data dimensions 
(PCs) onto two-dimensional circular space while VizRank, offers a heuristic search 
technique to guide the ordering of variables and evaluating the resulting radial 
projections by their ability to discriminate between classes. These radial 
visualization plots illustrate the clustering of spectra belonging to same class 
(assigned based on pathological assessment) and how well the classes are 
separated based on the PC scores. In this study, we used only the single best-
ranked projection for clustering displays. Finally, the spectra belonging to various 
pathologies were subjected to partial least squares-discriminant analysis (PLS-DA) 
[35] to quantify the diagnostic power of the recorded spectra. A PLS-DA derived 
decision model was built based on training data and the diagnostic power was 
independently tested by invoking an independent set of test spectra. In particular, 
60% of the spectra belonging to each class were randomly selected to train the 
model and the remaining 40% were tested using the model developed to check 
the classification capability of PLS-DA in identifying the pathology of the tissue. 
1000 iterations were performed keeping the same mixture of training: test data to 




Figure 2.2: SHINERS spectra of breast cancer. Average SHINERS spectra 
(solid line) and spontaneous Raman spectra (dotted line) acquired from fresh 
frozen sections of normal breast tissue (NB) as well as those displaying the 
following breast lesions: fibroadenoma (FD), atypical ductal hyperplasia (ADH), 
ductal carcinoma in situ (DCIS), and invasive ductal carcinoma (IDC).  
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2.3 Results  
The Raman spectral dataset obtained was classified as belonging to one of the 
following classes based on the consensus histological assessment. 17, 9, 11 and 
20 tissue sections were diagnosed as fibroadenoma (FD), atypical ductal 
hyperplasia (ADH), ductal carcinoma in situ (DCIS) and invasive ductal carcinoma 
(IDC), respectively. Additionally, 15 normal breast tissue (NB) sections were 
investigated for comparison with benign, premalignant and malignant pathologies. 
Among the diseased tissue sections, some exhibited the presence of type II 
microcalcifications (3 FD, 3 ADH, 5 DCIS and 4 IDC tissue sections) and were 
studied separately as they form an important class of pathological indicators in 
breast cancer diagnosis. 
2.3.1 Spontaneous Raman spectroscopy and SHINERS of tissues without 
microcalcifications  
Figure 2.2 shows the mean spontaneous Raman and SHINERS spectra of breast 
tissues without calcifications belonging to the different classes, i.e. NB, FD, ADH, 
DCIS and IDC (spectra are displayed vertically offset for visual clarity). It can 
clearly be seen that the Raman features were significantly enhanced by using 
SHINs enabling us to readily characterize the differences in spectral profiles of NB, 
FD, ADH, DCIS, and IDC tissue sections. The characteristic band assignments of 
the breast tissue, performed in our recent publication [33], indicate the presence 
of a similar set of chemical compounds, namely lipids, proteins, nucleic acids and 
β-carotenes. The main spectral features of normal breast tissue include peaks 
around 1300, 1442, and 1745 cm-1 that can be expectedly attributed to lipids (with 
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the corresponding lack of prominent protein or nucleic acid peaks) [36, 37]. 
Fibroadenoma shows similar characteristics as normal breast tissue except for the 
Raman band at 665 cm-1 that is characteristic of the C-S stretching mode of cystine 
[36, 37]. In comparison to normal breast tissue, ADH, DCIS and IDC tissues show 
stronger peaks located at 1004, 1033, 1610 and 1658 cm-1 from vibrational modes 
of proteins and at 970, 1090 and 1157cm-1 from DNA. These are indicative of 
higher concentration of proteins and nucleic acids in the diseased state. Closer 
inspection reveals that the concentrations of proteins and nucleic acids increase 
gradually while lipid content reduces in the pathological transition from ADH to IDC. 
Additionally, DCIS and IDC tissues feature the blue shifted and broad peak of CH2, 
which suggests fracture of acyl backbone of lipids and proteins [38] Also, the 
sensitive Raman features at 1090 cm-1, characteristic of the phosphate stretching 
vibration in DNA, shows a perceptible shift to 1086 cm-1 for DCIS and IDC hinting 
at the possible rupture of DNA strands with the further progression of cancer. A 
comprehensive list of the spectral features, and the associated peak shifts, 
corresponding to the different pathological classes is provided in our previous 




Figure 2.3: Spectroscopy histopathology comparisons for tissue section 
exhibiting ADH (top) and IDC with microcalcifications (bottom). (A) Mean 
SHINERS (solid line) and spontaneous Raman (dotted line) spectra acquired from 
the lesions; (B) images of the fresh frozen sections (without SHINs) that were 
employed in spontaneous Raman spectra acquisition. The locations of 
microcalcifications were highlighted by squares; (C) images of the fresh frozen 
sections after addition of SHINs. The locations of microcalcifications were 
highlighted by squares; (D) corresponding sections stained with H&E. The images 
represent an approximate area of 0.8 × 0.6 mm2. 
 
 
Our next aim was to correlate the spectroscopic measurements in both 
cases with the histological evaluation. Figure 2.3 shows a representative set of 
spontaneous Raman and SHINERS spectra recorded from ADH and IDC tissue 
sections, respectively, with the latter showing the presence of microcalcifications. 
Panel (D) of the figure exhibits the corresponding H&E stained section as well as 
the frozen contiguous sections without the addition of SHINs (Panel (B), from 
which the spontaneous Raman data was recorded) and post the addition of SHINs 
(Panel (C), from which the SHINERS data was recorded). Based on the PCA 
decomposition, the most significant PC scores were then employed to create a 
radial visualization map to evaluate the clustering of spectra belonging to the same 
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pathological class-or the lack thereof. Figure 2.4 displays the cluster maps for the 
four types of breast lesions (FD, ADH, DCIS, IDC) using five PC scores for 
spontaneous Raman (A) and SHINERS spectra (B), respectively. (The 
corresponding PC loadings are given in Fig. S2.1 of Appendix.)  
 
 
Figure 2.4: Multi-dimensional radial visualization plots for principal 
component (PC) scores obtained from SHINERS spectra of breast cancer. 
The specific PCs were selected using a heuristic search algorithm that enables 
maximal separation of the four diseased groups. (A) Spontaneous Raman spectra; 
(B) SHINERS spectra. The plots highlight the degree of clustering of sites 
belonging to a specific pathological class in the absence of microcalcifications for 
the two spectral datasets. 
 
From the figure, we observe that the sites belonging to a particular class 
show a tendency to cluster together, although there is considerable overlap 
between few of the classes particularly for (A) (spontaneous Raman spectra-based 
PC scores map). The Raman spectra-derived overlap is consistent with our 
previous report [12] where significant segmentation between the pathologies was 
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not observed visually-despite the absence of ADH from that dataset. This overlap 
is significantly reduced in Fig. 2.4B, which yields reasonably satisfactory (though 
not perfect) class boundaries. We attribute this qualitative enhancement in spectra-
based class separation to the enhancement of the subtle vibrational mode-specific 
spectral features by SHINs. 
 
Table 2.1. Summary of classification accuracies for PLS-DA derived decision 
algorithms featuring spontaneous Raman and SHINERS spectra, 
respectively. Standard deviations are noted in the parentheses. In this analysis, 
spectra and identity labels corresponding to normal breast (NB), fibroadenoma 
(FD), acute ductal hyperplasia (ADH), ductal carcinoma in situ (DCIS) and invasive 
ductal carcinoma (IDC) were included. 
 
Accuracy of spontaneous 
Raman spectroscopy 
Accuracy of SHINERS 
NB 72.8% (5.7%) 82.0% (5.1%) 
FD 91.0% (4.4%) 92.3% (2.5%) 
ADH 97.2% (1.7%) 97.5% (1.6%) 
DCIS 87.4% (6.0%) 92.7% (3.9%) 
IDC 96.9% (2.0%) 91.8% (4.0%) 
 
Quantitative assessment of the diagnostic capability can be obtained from 
the results of PLS-DA-derived decision algorithm summarized in Table 2.1. Using 
independent training and test sets, we computed the overall accuracy of the PLS-
DA derived decision algorithms in classifying NB, FD, ADH, DCIS and IDC to be 
72.8%, 91.0%, 97.2%, 87.4% and 96.9%, respectively using spontaneous Raman 
spectroscopy. The analogous PLS-DA derived decision models for the SHINERS 
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data yielded mean classification accuracy of 82.0%, 92.3%, 97.5%, 92.7% and 
91.8%, respectively. Despite the extremely challenging cohort studied here (as 
reflected by the presence of ADH, DCIS and IDC sites), Raman spectroscopy (both 
spontaneous and enhanced) offer significant spectral markers of the (downstream) 
molecular determinants in the epithelial and stromal tissue components. 
Specifically, when used in conjunction with chemometric methods, these spectral 
profiles enable objective disease detection with high diagnostic accuracy. The 
overall classification performance rose for all categories from spontaneous Raman 
to SHINERS, barring IDC, with significant improvements for normal breast tissue 
and DCIS segmentation. The inferior performance of DCIS classification using 
spontaneous Raman spectra is reflective of the large spread observed in Fig. 2.4A, 
while the reduced classification accuracy of IDC for SHINERS can also be 
predicted based on the dispersion of the IDC sites in Fig. 2.4B.  
2.3.2 Spontaneous Raman spectroscopy and SHINERS of tissues with type 
II microcalcifications 
Raman spectroscopy has been previously investigated in formalin-fixed, paraffin-
embedded sections for detection of type I and II breast microcalcifications as well 
as for the classification of type II microcalcifications related to benign and 
malignant lesions [39]. More recently, we have also developed Raman 
spectroscopy algorithms to detect microcalcifications in fresh breast needle biopsy 




Figure 2.5: SHINERS spectra of breast microcalcifications. Average SHINERS 
spectra (solid line) and spontaneous Raman spectra (dotted line) acquired from 
tissue sites displaying type II microcalcifications with the following breast 
pathologies: fibroadenoma (FD), atypical ductal hyperplasia (ADH), ductal 
carcinoma in situ (DCIS), and invasive ductal carcinoma (IDC). 
 
Here, Fig. 2.5 shows the mean spectra of tissues showing presence of 
microcalcifications with and without SHINs measured from fresh frozen sections of 
FD, ADH, DCIS, and IDC tissue. The major peak at ca. 960 cm-1 is a well-known 
calcium hydroxyapatite peak and can be ascribed to the totally symmetric 
stretching mode of the “free” tetrahedral phosphate ion [39-41]. The other 
noticeable peaks appear at 1002, 1072, 1156, 1446, and 1663 cm-1 that are 
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attributed to amino acid residue (phenylalanine) [42], nucleic acids, lipids, 
carotenoids, and amide-I, respectively [36, 37]. FD and ADH microcalcifications 
spectra exhibit a peak at 1072 cm-1, which corresponds to the O-P-O stretch of 
nucleic acids, whereas in DCIS and IDC tissues the feature is observed to be red-
shifted to 1078 cm-1. The spectra belonging to ADH show a stronger characteristic 
amide-I peak at 1657 cm-1 while DCIS tissue sites harboring microcalcifications 
show the presence of relatively stronger peaks corresponding to amino acid 
residue (phenylalanine) at 1003, 1031 cm-1 and lipids (CH2 and CH3 bending) at 
1301, 1441 cm-1. Also, compared to the DCIS sites, the spectra recorded from IDC 
sites with microcalcifications show stronger nucleic acids peaks and weaker lipids 
peaks. 
Figure 2.6 shows the corresponding radial visualization plot employing 
selected PC scores to depict maximum class separation of the four diseased 
classes. (The corresponding PC loadings are given in Fig. S2.1 of Appendix.) 
Once again, it is evident that the addition of SHINs improves the separation 
between sites belonging to the same pathological class. A comparison of Fig. 2.4 
and Fig. 2.6 reveals that the separation for both spontaneous Raman and 
SHINERS data is much improved for the tissue sites harboring microcalcifications. 
To quantitatively evaluate the diagnostic advantage provided by 
microcalcifications in classifying the diseased tissues, PLS-DA was employed to 
develop decision models, as detailed earlier. The results obtained are summarized 
in Table 2.2. In this analysis restricted to sites harboring microcalcifications alone, 
classification accuracies of 99.0%, 98.1%, 96.9% and 100% were achieved for the 
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classes FD, ADH, DCIS and IDC respectively, using spontaneous Raman 
spectroscopy. The PLS-DA derived decision models for SHINERS, on the other 
hand, yielded accuracies of 99.9%, 99.9%, 97.5% and 98.2% for the same 
pathologies. Clearly, the multivariate analysis corroborates the visual findings that 
the accuracy of classification is higher for tissues harboring microcalcifications in 
comparison with those that show no microcalcifications. Detection of such 
biomineralization processes is of value not only in examining breast pathology but 
also in recognizing mineralized deposits in other organs, including the thyroid [43] 
and middle ear [44]. 
2.4 Discussion 
The results of the present study demonstrate the ability of label-free Raman 
spectroscopy to differentiate closely related breast pathologies. Furthermore, the 
improvement of the classification results and the class separation in radial plots 
with the addition of SHINs underscores their diagnostic utility in tissue 
spectropathology. These two label-free approaches collectively offer a powerful 
tool to measure both localized cellular changes (especially in the case of SHINERS, 
since SERS presents a very surface selective method due to the decay of field 
enhancement with r-3) [45] and the tissue microenvironment. While a critical role 
for the stromal environment is acknowledged in the onset and progression of 
cancer [46], existing diagnostic methods largely focus on the characterization of 
epithelial cells-a barrier that can be overcome by the employment of the employed 





Figure 2.6: Multi-dimensional radial visualization plots for principal 
component (PC) scores obtained from SHINERS spectra of breast 
microcalcifications. Radial visualization map using principal component (PC) 
scores that provide maximal separation between tissues sites belonging to 
different pathologies and harboring microcalcifications. (A) Spontaneous Raman 
spectra; (B) SHINERS spectra. 
 
 
Table 2.2: Summary of classification accuracies for PLS-DA derived decision 
algorithms featuring spontaneous Raman and SHINERS spectra, 
respectively. Standard deviations are noted in the parentheses. In this analysis, 
spectra and identity labels corresponding to tissue sites harboring 
microcalcifications and displaying the following pathologies were included: 
fibroadenoma (FD), acute ductal hyperplasia (ADH), ductal carcinoma in situ 
(DCIS) and invasive ductal carcinoma (IDC). 
 
Accuracy of spontaneous 
Raman spectroscopy 
Accuracy of SHINERS 
FD 99.0% (1.5%) 99.9% (0.2%) 
ADH 98.1% (6.3%) 99.9% (1.7%) 
DCIS 96.9% (2.6%) 97.5% (2.8%) 




Significantly, the developed multivariate decision models were able to 
exploit the molecular structural differences - as indicated by spectral peak shifts, 
band shapes and relative intensity changes occurring across the Raman spectrum 
- to identify ADH, a benign lesion of the breast that indicates an increased risk of 
breast cancer. This differentiation has represented an outstanding challenge for 
most non-invasive photonic tools, due to its similarity to low-grade DCIS - 
cytologically, architecturally and on a molecular basis. In fact, early and accurate 
detection of ADH and DCIS prior to their progression into invasive disease 
represents a key goal in breast cancer diagnostics [47]. We observed the spectral 
markers representative of vibrational modes of proteins and nucleic acids increase 
gradually while those of lipids reduce in the pathological progression from ADH to 
IDC. In addition, the CH2 and the C=O stretching mode of phospholipids showed 
a consistent 2-3 cm-1 blue shift in DCIS and IDC tissues, due to lipid peroxidation 
that occurs in the process of canceration [38]. Based on these findings, this study 
provides a significant extension to the literature by accurately differentiating these 
closely related pathologies (especially ADH and DCIS) in fresh frozen tissues 
(rather than in deparaffinized sections that may introduce spectral artifacts [48]. 
Perhaps surprisingly, the accuracy of classification for normal breast tissue using 
both spontaneous Raman spectroscopy and SHINERS was found to be lower than 
diseased tissues (ca. 73% and 82% respectively) in the recorded dataset. We 
attribute this to the probable presence of some uninvolved tissue sites in the 
diseased pathology categories that would then skew the classification model 
trained on spectra originating from such sites.  
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We have also discovered the presence of subtle, but reproducible, 
differences in the chemical composition of tissue sites harboring type II 
microcalcifications among the four kinds of studied lesions. It was observed that 
the peak of O-P-O stretch of nucleic acids at 1072 cm-1 in the spectra of FD and 
ADH tissues shifted to 1078 cm-1 for DCIS and IDC tissues, as a result of the 
changed calcification compositions of different kinds of diseases. Moreover, the 
ADH sites exhibit a significant amide-I peak at 1657 cm-1; in contrast, the same 
peak loses its intensity in DCIS and IDC tissues owing to the process of 
canceration whereby the protein conformation is damaged to varying degrees. 
A further important goal of this work was to compare the diagnostic power 
of SHINERS based decision models to that derived from spontaneous Raman data. 
We find that, on average, the performance of the SHINERS decision models 
supersedes that of its spontaneous Raman counterpart. This is also reflected in 
the clearer clustering of the SHINERS based PC scores corresponding to the 
different pathologies in the radial visualization plots. A slight decrease in the 
classification accuracy of IDC sites (with and without microcalcifications) is 
observed for SHINERS in relation to spontaneous Raman measurements. While 
the precise rationale for this is the subject of ongoing investigations in a larger 
patient cohort, a plausible explanation lies in the (sharper) differences in the nature 
of molecular changes that appear in IDC among different patients due to its higher 
degree of malignancy. Following the enhancement of spectral features by 
SHINERS, these inter-lesion differences are amplified resulting in worse 
performance of the multivariate classification models.  
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Finally, the intensity ratios of the key lipid, protein and nucleic acid peaks 
underscore the improvement in signal sensitivity due to the incorporation of SHINs 
and indicate that a significant reduction in SHINERS acquisition time could still 
result in nearly equivalent spectral profiles as obtained in the spontaneous Raman 
measurements. This has substantive implications for Raman spectroscopic 
imaging, which would overcome the sampling limitations of single point recordings 
and combine the molecular and spatial information content into a hyperspectral 
dataset. Unlike targeted SERS probes, where the SERS reporters transduce the 
presence of the biochemical analytes of interest into measurable signals, 
SHINERS allows the enhancement of the intrinsic vibrational modes of all the 
molecular species present in the probed specimen. This ensures the retention of 
the exquisite molecular specificity of spontaneous Raman spectroscopy thereby 







Figure S2.1: The principal component loadings (PCs) used to draw radial 
visualization plots used in Fig. 2.4. (A) Spontaneous Raman spectra from 




Figure S2.2: The principal component loadings (PCs) used to draw radial 
visualization plots used in Fig. 2.6. (A) Spontaneous Raman Spectra from 
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Mapping the genetic basis of breast microcalcifications and their 
role in metastasis 
  
Breast cancer screening and early stage diagnosis is typically performed by X-ray 
mammography, which detects microcalcifications. Despite being one of the most 
reliable features of nonpalpable breast cancer, the processes by which these 
microcalcifications form are understudied and largely unknown. In the current work, 
we have investigated the genetic drivers for the formation of microcalcifications in 
breast cancer cell lines and have investigated their involvement in disease 
progression. We have shown that stable silencing of the Osteopontin (OPN) gene 
decreased the formation of hydroxyapatite in MDA-MB-231 breast cancer cells in 
response to osteogenic cocktail. In addition, OPN silencing reduced breast cancer 
cell migration. Furthermore, breast cancer cells that had spontaneously 
metastasized to the lungs in a mouse model of breast cancer had largely elevated 
OPN levels, while circulating tumor cells in the same mouse model contained 
intermediately increased OPN levels as compared to parental cells. The observed 
dual roles of the OPN gene reveal the existence of a direct relationship between 
calcium deposition and the ability of breast cancer cells to metastasize to distant 
organs, mediated by common genetic factors.  
 
 This chapter is a reprint of the peer-reviewed publication: Rizwan A*, Paidi SK*, Zheng C*, Cheng 
M, Fan Z, Barman I, Glunde K. “Mapping the genetic basis of breast microcalcifications and their 





Breast cancer is the most common malignancy in women with an incidence rate of 
about 120 in 100,000 women in the United States [1]. The 5-year survival rate of 
breast cancer patients drops from ~99% for Stage I patients, to ~27% for Stage IV 
disease, and thus necessitates early detection [1]. Mammography to reveal 
microcalcifications in the breasts is the most widely used tool in breast cancer 
screening and for the initial diagnosis of non-palpable breast tumors [2]. The use 
of microcalcifications as a reliable biomarker of breast cancer has also been 
questioned due to their association with both benign and malignant lesions, which 
leads to unnecessary biopsies [3,4]. Specifically, microcalcifications that are 
composed of calcium hydroxyapatite are found in both benign breast lesions and 
breast cancers whereas those constituted by calcium oxalate crystals are largely 
indicative of benign lesions. For several decades, research has mostly focused on 
recognizing the various morphologies that microcalcifications can have in breast 
tissue and their correlation with the degree of malignancy [5]. Emerging evidence 
from us and others suggests that higher hydroxyapatite content in mammary 
microcalcifications is a marker for malignant disease whereas lower 
hydroxyapatite and a relatively higher calcium carbonate content is characteristic 
of benign breast lesions [6]. Yet, such studies have provided limited information 
about the mechanisms governing the genesis of microcalcifications and their role 
in disease progression. 
After having collectively been viewed as a result of cellular degeneration, a 
paradigm shift has recently been proposed that specific type(s) of 
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microcalcifications are products of active cellular processes and may result from 
processes similar to those involved in physiological bone mineralization [7,8]. 
Bellahacene et al. reported increased expression of bone matrix proteins, which 
are typically involved in physiological bone mineralization, in human breast cancer 
cells, and speculated that they may have a role in hydroxyapatite formation [9,10]. 
Recently, Scimeca et al. showed that, under specific stimuli, epithelial cells 
undergoing epithelial-mesenchymal-transition (EMT) transform themselves into 
cells with an osteoblast-like phenotype, and are able to contribute to the production 
of breast microcalcifications [11]. They further demonstrated that the localization 
of hydroxyapatite in these cancer cells was similar to that in osteoblasts. These 
observations suggest that to understand the role of microcalcifications in breast 
cancer, it is imperative to systematically explore the genetic basis of their formation, 
subsequent transportation into the extracellular matrix and involvement in 
metastatic cancer progression. 
In the current study, we seek to identify and study key genetic factors that 
guide the formation of microcalcifications from mammary cells, and their 
relationship with the migration capabilities of human breast cancer cells. To 
achieve this, we have examined publicly available microarray data sets for 
potential gene candidates in a blinded and unbiased fashion, which are 
differentially expressed in aggressive human breast cancer cell lines that typically 
develop microcalcifications in vitro compared to non-aggressive lines. The 
obtained list of candidate genes was further refined by selecting genes encoding 
proteins that have putative roles in tissue or cellular microcalcification. We 
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identified the SPP1 gene encoding osteopontin (OPN) to be the most differentially 
expressed gene characteristic of aggressive cell lines in our list of genes. 
Osteopontin (OPN) is a secreted soluble glycoprotein that is present in most body 
fluids including milk and serum [12]. It is overexpressed in a number of different 
carcinomas and has previously been implicated as an enhancer of mineralization 
in human breast cancer samples9. Secreted OPN interacts with multiple cell 
surface receptors, including various integrins (integrin β1, integrin β3) and CD44 
[13]. Several studies have proposed a link between OPN and cancer [14–20]. This 
link, in particular to metastasis, is based on the binding of OPN to cell surface 
receptors such as CD44, which is critical to EMT initiation and cell-matrix adhesion 
in various types of primary tumors [21–23]. 
Through shRNA knockdown of OPN in human MDA-MB-231 breast cancer 
cells, we have shown a direct involvement of the OPN gene in the formation of 
microcalcifications. Moreover, OPN knockdown resulted in reduced migration in in 
vitro assays, which was mediated at least in part by reduced CD44. The 
contribution of OPN to the migratory properties of the cancer cells was validated 
through in vivo studies by quantifying and comparing levels of OPN and CD44 
expression in parental MDA-MB-231 cells orthotopically implanted in the mouse, 
MDA-MB-231 cells that have escaped from the primary tumor into the blood 





3.2.1 Osteopontin expression increases with breast cancer cell 
aggressiveness and osteogenic cocktail treatment 
We used the GEO dataset GSE16795, which contains gene expression profiles of 
39 human breast cancer cell lines and divided it into two groups of five metastatic 
and five non-metastatic with high relevance to our experimental work [24]. Among 
the genes that are differentially expressed in metastatic versus non-metastatic cell 
lines, the genes encoding proteins with putative roles in the context of breast 
microcalcifications are shown in Fig. 3.1A in decreasing order of their log two-fold 
change. Figure 3.1A also shows the differential expression of the listed genes 
across the cell lines in the dataset as a heat map. Specifically, gene expression 
levels of OPN were found to be significantly (p-value = 0.0047) elevated (~29 fold) 
for the metastatic group compared to the non-metastatic group. We analyzed the 
protein-protein interactions of significantly differentially expressed genes in the 
selected metastatic versus non-metastatic cell lines from GSE16795 using the 
STRING-10.5 (http://string-db.org) analysis software and database [25]. Figure 
3.1B visualizes a subset of the identified biological processes and pathways that 
involve OPN (SPP1). Network nodes are colored by pathway membership, and 
pathways are sorted by increasing false discovery rate. Pathways that were most 
significantly activated, i.e. cell migration, extracellular matrix organization, tissue 
development, and chemotaxis, were also circled in the same color as the 
corresponding nodes. Additional pathways with significant activation in metastatic 
cells that involve OPN were response to extracellular stimulus, regulation of 
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response to external stimulus, cell adhesion, regulation of cell differentiation, and 
focal adhesion. Solid and dotted lines represent intra-cluster and inter-cluster 
functional associations, respectively. As seen from Fig. 3.1B, OPN (SPP1) directly 
interacts with CD44 and FGF2, which in turn interact with several other proteins, 
including vimentin (VIM) through CD44. 
As the next step, we cultured metastatic (MDA-MB-231 and SUM-149) and 
non-metastatic (BT-474 and T47D) human breast cancer cell lines and 
characterized their OPN mRNA expression levels as determined by qRT-PCR. To 
assess the relationship between calcification status and OPN expression level, the 
same cell lines were cultured in media enriched with osteogenic cocktail for 
induction of microcalcifications. Figure 3.2A shows the OPN mRNA expression 
results in the presence of osteogenic cocktail. The OPN mRNA expression levels 
of cells cultured in the absence of osteogenic cocktail are shown alongside for 
comparison. The OPN mRNA expression levels are significantly higher in both of 
the metastatic as compared to both of the non-metastatic breast cancer cell lines. 
It is also evident that OPN expression increases substantially with the addition of 
exogenous phosphates in the form of osteogenic cocktail, indicating that OPN may 
play a crucial role in mediating the formation of microcalcifications in breast cancer 
cells. The metastatic triple-negative human breast cancer cell line MDA-MB-231 





Figure 3.1: Gene expression analysis of microcalcifications in breast cancer 
cells. (A) Expression profiles of genes relevant to breast microcalcifications that 
are differentially expressed in metastatic and non-metastatic breast cancer cell 
lines. The gene expression heat map focused on genes directly linked to 
microcalcifications was obtained by subjecting the publicly available microarray 
dataset GSE16795 to the Gene-e matrix visualization and analysis platform. From 
the 38 cell lines included in the dataset, 5 non-metastatic and 5 metastatic cell 
lines with high relevance to our experimental work were identified and utilized to 
generate the heat map. (B) Protein-protein interaction network of differentially 
expressed genes in the selected metastatic versus non-metastatic cell lines. 
Identified biological processes and pathways that involve OPN (SPP1) are shown. 
Network nodes are colored by pathway membership, and pathways are sorted by 
increasing false discovery rate. Interactions are colored by type of interaction as 
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listed in the legend. Solid and dotted lines represent intra-cluster and inter-cluster 
functional associations, respectively. 
3.2.2 Stable shRNA silencing of OPN inhibits the formation of cellular 
microcalcifications 
To study the role of the OPN gene (SPP1) in the formation of microcalcifications 
in MDA-MB-231 cells, stable clones were generated using shRNA knockdown of 
the SPP1 gene in these cells. Four stable clones - shOPN1 through shOPN4 - 
were identified, characterized, and used for further studies. Figure 3.2B shows 
significantly reduced OPN mRNA expression levels in the stably OPN silenced 
lines versus empty-vector control cells, confirming sufficient shRNA gene 
knockdown. Stably silenced clones and control cells were sub-cultured in the 
presence of osteogenic cocktail for 7 days to induce the formation of 
microcalcifications. The cells were fixed and stained with alizarin red S to 
selectively report for the presence of microcalcifications. Figure 3.3A shows 
representative images of stably OPN silenced MDA-MB-231 clones and control 
cells stained with alizarin red for qualitative comparison. Three independent 
batches of cells were stained, and the average calcification content of the cells is 
shown in Fig. 3.3B along with standard deviations. Our observations reveal that 
there is a consistent inhibition of the formation of cellular microcalcifications due to 
OPN gene silencing in the knockdown clones. The similarity in the trend of 
variation in level of OPN mRNA expression and cellular calcification content across 
the knockdown clones further strengthens our hypothesis that the OPN gene 









Figure 3.2: OPN mRNA expression of breast cancer cells in osteogenic 
cocktail. (A) Enhancement of OPN mRNA levels in metastatic (MDA-MB-231 and 
SUM 149) and non-metastatic (BT-474 and T47D) cell lines in response to addition 
of osteogenic cocktail. Relative expression levels of OPN mRNA in selected cell 
lines (analyzed using qRT-PCR) in response to osteogenic cocktail is shown. The 
expression levels of OPN in cells grown in control media are shown alongside for 
comparison. (B) Generation of stable clones that exhibit reduced OPN expression 
using shRNA silencing of the SPP1 (i.e OPN) gene in MDA-MB-231 cells. Relative 
expression of OPN mRNA in stably silenced clones (analyzed using qRT-PCR) in 
response to osteogenic cocktail is shown. Conventional Student t test threshold 









Figure 3.3: Silencing of OPN gene results in inhibition of cellular 
microcalcification formation in the knockdown clones. (A) Representative 
bright-field images showing alizarin red S stained cells for the four stably silenced 
clones and vector control. The scale bars represent 50 µm. (B) Bar plot showing 
mean and standard deviation of normalized alizarin red S stain intensity for stably 
silenced clones as percentage of vector control. Conventional Student t test 




3.2.3 Stable OPN silencing reduces the migration of aggressive MDA-MB-231 
cells 
The impact of stable OPN silencing on the migration of MDA-MB-231 cells was 
tested using transwell migration assays. All four stably OPN silenced MDA-MB-
231 lines employed in the study, shOPN1 through shOPN4, displayed reduced cell 
migration compared to control cells. Figure 3.4 shows representative migration 
assay images along with the quantitative comparison of migration ability for all the 
clones studied. The differences in migration ability were statistically significant for 




Figure 3.4: Silencing of OPN gene results in reduction of in vitro migration 
potential of the knockdown clones. (A) Representative bright-field images 
showing crystal violet stained membranes of transwell inserts for the four stably 
silenced clones and vector control. The scale bars represent 200 µm. (B) Bar plot 
showing mean and standard deviation of number of migrated cells for stably 
silenced clones as percentage of vector control. Conventional Student t test 




3.2.4 Over-expression of OPN in circulating tumor cells (CTC) and lung 
metastatic cells (LMC) 
Motivated by the reduction of migration capabilities of the cells in the in vitro 
experiments, we performed orthotopic inoculations of MDA-MB-231 breast cancer 
cells and derived MDA-MB-231 tumor cells from the blood circulation (circulating 
tumor cells, CTC) and lungs (lung metastatic cells, LMC) at 8–12 weeks following 
inoculation as shown in Fig. 3.5A. These CTC and LMC were examined to verify 
the relevance of our findings in vivo. Figure 3.5B shows the mean and standard 
deviation of OPN mRNA expression levels comparatively for parental MDA-MB-
231 cells, CTC, and LMC. The observations reveal 80-fold and 160-fold increased 
expression of OPN in CTC and LMC, respectively, as compared to the parental 
MDA-MB-231 cells. We also tested the expression levels of two of the genes 
identified as interacting with OPN in our protein-protein interaction analysis (Fig. 
3.1B), which are involved in cell migration, extracellular matrix organization, and 
cell adhesion. The means and standard deviations of CD44 mRNA (Fig. 3.5C) and 
VIM mRNA (Fig. 5D) expression levels are shown comparatively for parental MDA-
MB-231 cells, CTCs, and LMCs. We observed significant decreases in CD44 
mRNA expression in CTCs and LMCs compared to parental MDA-MB-231 cells. 
VIM mRNA expression was significantly increased in CTCs and LMCs. Differences 









Figure 3.5: In vivo migration of MDA-MB-231 cells is dependent on 
expression of OPN. (A) Schematic of in vivo study conducted to isolate 
fluorescent tumor cells of varying metastatic potential from blood and metastatic 
lungs of mice carrying orthotopic MDA-MB-231 xenograft. Bar plots showing mean 
and standard deviation of (B) OPN mRNA, (C) CD44 mRNA, and (D) VIM mRNA 
expression for circulating tumor cells (CTCs) and lung metastatic cells (LMCs) 
relative to parental MDA-MB-231 cells. Conventional Student t test threshold 





Cellular mechanisms driving the formation of mammary microcalcifications in 
breast cancer cells remain unclear despite their extensive use in breast cancer 
screening and staging. Since the molecular biology of the formation of 
microcalcifications in breast cancer is poorly understood, we performed an initial 
in silico screen using an existing mRNA database for comparing highly metastatic 
breast cancer cell lines with non-metastatic breast cancer cell lines. In this screen, 
we selectively considered genes with a putative direct or indirect relationship with 
breast microcalcifications or bio-mineralization in general. Osteopontin, the protein 
encoded by the gene SPP1, which had the highest differential expression in our 
analysis, has previously been associated with both physiological and pathological 
mineralization in various organs, making it a good candidate gene for further 
investigation [9]. The increased expression of this gene in MDA-MB-231 cells in 
response to osteogenic cocktail treatment further supported the possibility of its 
involvement in inducing mammary mineralization. The osteogenic cocktail we used 
is known to induce intracellular mineralization comprising of calcium 
hydroxyapatite due to the increased availability of phosphate in the cell culture 
media with addition of β-glycerophosphate, and therefore has emerged as a 
popular in vitro model for studying mineralization [26]. 
The significant suppression of intracellular mineralization as assessed by 
alizarin red S staining of cells cultured in osteogenic cocktail in stably OPN 
silenced MDA-MB-231 cells suggests that OPN is one of the principal factors 
directly governing cellular mineralization processes in triple-negative breast cancer 
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cells. Studies in the past have shown that OPN is critical for both promotion and 
inhibition of hydroxyapatite formation in normal bone and connective tissue cells 
[27,28]. More recently, it has been reported that the regulation of hydroxyapatite 
formation depends on the phosphorylation state of OPN and its interactions with 
other molecules such as osteocalcin [29]. OPN also has been reported to act as 
hydroxyapatite nucleator when present in certain suitable conformations [29]. 
Based on this evidence and the results presented in this study, we reason that the 
formation of microcalcifications in breast cancer cells is a result of the availability 
of OPN in its phosphorylated state, and its dynamic interaction with several other 
proteins.  
Our observation that OPN regulates the formation of microcalcifications in 
breast cancer cells is in agreement with recent observations by Scimeca et al. that 
mammary microcalcifications are found in breast epithelial cells that have 
developed an osteoblast-like phenotype [11]. Such osteoblast-like cells developed 
from breast epithelial cells that were triggered by β-microglobulin to acquire 
mesenchymal characteristics. The osteoblast-like phenotype was sustained by 
bone morphogenic protein-2 (BMP-2), and these cells exhibited localized 
hydroxyapatite-rich cytoplasmic vesicles similar to hydroxyapatite containing 
intracellular vesicles found in osteoblasts [11]. In the same study, increased focal 
expression of OPN was observed in the proximity of hydroxyapatite, which was 
also a characteristic feature of lesions in biopsied tissues, showing 
microcalcifications along with increased mesenchymal markers such as VIM. This 
observation is consistent with significantly increased expression levels of the 
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genes encoding OPN and VIM in our microarray analysis as well as in our animal 
model of spontaneous dissemination, in which CTCs and LMCs concurrently 
displayed elevated levels of OPN and VIM as compared to parental human MDA-
MB-231 breast cancer cells. Together, our results support the notion that 
microcalcifications in aggressive breast cancer cells are driven by processes 
similar to that govern physiological mineralization. 
Furthermore, the relationship between the microcalcification status of 
breast cancer cells and their metastatic capabilities remains largely unexplored. In 
our microarray analysis of publicly available data, we observed that OPN was 
significantly involved and interacted with cell migration, extracellular matrix 
organization, chemotaxis, and cell adhesion in metastatic breast cancer cells. 
Motivated by these data and the finding that microcalcifications are preferentially 
produced in cells displaying a mesenchymal phenotype, we assessed the effect of 
stable OPN knockdown on the migration capabilities of MDA-MB-231 cells. The 
significant inhibition of migration that we detected in all knockdown clones in in 
vitro transwell migration assays indicates that OPN expression directly affects the 
migration abilities of breast cancer cells. Our results are in good agreement with a 
recent study by Zhang et al., in which OPN knockdown in breast cancer cells 
resulted in integrin-induced inhibition of cell migration and invasion, and promoted 
apoptosis through induction of autophagy and inactivation of PI3K/Akt/mTOR 
pathway [30]. Our data also agree with recently published data showing that 
transient siRNA knockdown of OPN in murine mammary tumor cell lines reduced 
cell migration [31]. 
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From an orthotopic mouse xenograft model of spontaneous metastasis in 
vivo, we observed that the OPN mRNA expression level from MDA-MB-231 cells 
that had spontaneously metastasized to the lungs (LMC) were significantly higher 
than that from circulating tumor cells (CTC) from the same model, which in turn 
were significantly higher than that in parental cells. These progressively increasing 
OPN levels in MDA-MB-231 cells of the same genetic background, which have 
progressively traveled farther down the metastatic cascade confirms in an in vivo 
system of spontaneous metastasis that dramatically increased OPN levels are 
most likely required for MDA-MB-231 cells to metastasize. These observations 
further suggest that the OPN gene is expressed differentially in the same 
aggressive breast cancer cell type depending on where these cancer cells are in 
their metastatic journey. 
Concurrently, we observed progressively decreased expression levels of 
CD44, which were highest in parental MDA-MB-231 cells, significantly decreased 
in CTCs, and the most dramatically decreased in LMCs. CD44 is a cell surface 
glycoprotein involved in cell communication and adhesion between adjacent cells 
and between cells and the extracellular matrix [32]. Reduced CD44 expression 
levels were previously shown to enhance breast cancer metastasis [33], which is 
in good agreement with our observations. Our studies thus provide further proof 
for an interaction between OPN and CD44 that helps aggressive breast cancer 




We also observed that the expression of VIM was significantly enhanced in 
CTCs and LMCs as compared to parental MDA-MB-231 cells. VIM is an 
intermediate filament protein that induces changes in the shape and motility of cells 
that are undergoing EMT [34,35]. Triple-negative breast cancers were previously 
shown to display elevated VIM expression levels compared to other types of breast 
tumors [36]. High expression levels of VIM in primary breast cancers were reported 
to support the formation of metastases in distant organs [37]. Taken together, our 
observations reinforce that an OPN-CD44-VIM interaction axis with implications in 
inducing EMT and reducing adhesion, helped triple-negative MDA-MB-231 cells to 
disseminate and form distant metastases. 
Due to its active role in the regulation of several key pathways that have 
implications in disease progression, OPN is emerging as a novel therapeutic target 
[38,39]. The findings of the current study may enable accurate monitoring of 
response to such therapy through the evaluation of changes in microcalcification 
status. In addition, by exploring the relationship between OPN therapy and its 
impact on metastatic progression, changing microcalcification status can 
potentially be utilized as a marker to track metastatic development. 
In conclusion, two major findings suggest the possibility of a fundamental 
relationship between mammary microcalcifications and metastatic capabilities of 
the cells in which they are formed. These findings are: (i) breast lesions rich in 
hydroxyapatite-based microcalcifications are associated with poor prognosis6, and 
(ii) evidence presented here that OPN is positively regulating both cellular 
microcalcification as well as breast cancer cell migration and metastasis, which 
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may occur through the observed OPN-CD44-VIM axis. Future studies further 
exploring the causal molecular relationship between microcalcifications and 
metastasis in breast cancer are important for a comprehensive understanding of 
microcalcification etiology and their improved use as diagnostic and prognostic 
marker in breast cancer. 
3.4 Materials and methods 
3.4.1 Identification of candidate genes responsible for breast 
microcalcifications 
The publicly available breast cancer microarray dataset GSE 16795 was analyzed 
where multiple breast cancer cell lines were grown to optimal cell densities for 
mRNA extraction and hybridization on Affymetrix microarrays [24]. A heat map was 
generated using the Gene-e matrix visualization and analysis platform 
(http://www.broadinstitute.org). This heat map represents changes in relative 
content of mineralization-related gene expression levels in 5 metastatic breast 
cancer cell lines (MDA-MB-231, MDA-MB-435s, SK-BR-7, SUM102PT, 
SUM149PT) and 5 non-metastatic breast cancer cell lines (BT-474, BT-483, MCF7, 
MDA-MB-415, T47D). 
3.4.2 Protein–protein interaction network 
The prominent genes overexpressed in the selected metastatic cell lines in the 
Gene-e analysis were employed to visualize protein-protein interactions using the 
STRING-10.5 (http://string-db.org) computational tool and database with a high 
confidence interval of 0.7 [25]. The STRING network, composed of the functional 
protein associations is based on genomic context, high-throughput experiments, 
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co-expression, and scientific reports. Functional enrichments in the network were 
identified using the STRING tool, and a subset of the identified biological 
processes and pathways that involve OPN (SPP1) were selected for visualization. 
The nodes in the network are colored according to their membership in each of the 
identified pathways and the pathways are sorted in the legend by increasing false 
discovery rates. 
3.4.3 Cell culture 
The human breast cancer cell lines MDA-MB-231, SUM 149, BT-474 and T47D 
were obtained from the American Type Culture Collection (ATCC, MD) [40]. All cell 
lines were cultured in RPMI 1640 (Sigma-Aldrich) supplemented with 10% fetal 
bovine serum, 100 U/ml penicillin, 100 µg/ml streptomycin and 2 µg/ml fungizone 
antimycotic (Life Technology, Grand Island, NY, USA) and maintained in a 
humidified incubator in 5% CO2 at 37 °C. In a subset of the studies, the cell culture 
media was supplemented with an osteogenic cocktail containing 10 mM β-
glycerophosphate (Sigma-Aldrich) and 50 mg/ml-1 ascorbic acid (Sigma-Aldrich) 
for promoting the formation of microcalcifications. 
3.4.4 Generation of stably OPN silenced breast cancer cell lines 
MDA-MB-231 cells were transfected with lentiviral particles expressing shRNA 
against human OPN (sc-36129-V, Santa Cruz Biotechnology, Dallas, Texas) to 
specifically knockdown the expression of the human OPN gene. These OPN 
shRNA lentiviral particles were purchased as a pool of concentrated, transduction-
ready viral particles containing 3 target-specific constructs that encode 19–25 nt 
(plus hairpin) shRNA designed to knock down OPN gene expression. Stably 
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transduced clones were developed, along with a vector control cell line expressing 
a control shRNA lentiviral particle (sc-108080, Santa Cruz Biotechnology). qRT-
PCR to measure OPN mRNA and immunoblotting of OPN confirmed successful 
transduction. For stably expressing lines, transfected cells were passaged and 
maintained in media containing Puromycin dihydrochloride (sc-108071, Santa 
Cruz Biotechnology). Cells were kept under selection for 7–10 days. Then, the 
cells from the selection step were plated at a density of 10 cells per ml in a 96-well 
tissue culture plate by adding 100 µl per well (i.e., 1 cell per well). Selected single-
colony wells in the 96-well tissue culture plate were expanded to high confluence 
and transferred to a 24-well tissue culture plate. Once the colonies in 24-well tissue 
culture plates were expanded to high confluence, they were passaged to a 6-well 
tissue culture plate. Clonal cell lines were assessed by qRT-PCR to select lines 
with significantly decreased levels of OPN gene expression. 
3.4.5 qRT-PCR 
Three cell lines from each group (MDA-MB-231, CTC, LM) were analyzed for gene 
expression with two technical repeats and two biological repeats each. For RNA 
purification, cells were grown for 48 hours in exponential growth phase and mRNA 
was isolated and purified using the RNeasy total RNA isolation kit (Qiagen, 
Germantown, MD) according to the manufacturer’s protocol. mRNA was reverse 
transcribed into cDNA using qScript™ cDNA SuperMix (Quanta Bioscience, 
Gaithersburg, MD). Quantitative real-time PCR (q-RT-PCR) was performed using 
IQ SYBR Green Supermix and gene-specific primers in the iCycler RT-PCR 
detection system (Bio-Rad, Hercules, CA) with 2 µl of diluted cDNA samples (1:10) 
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used as a template using the following primers. The sequences for forward and 
reverse primers for quantifying SPP1 mRNA, which expresses the OPN protein, 
were 5′-CGAGGTGATAGTGTGGTTTATGG-3′ and 5′-
GCACCATTCAACTCCTCGCTTTC-3′, respectively. The sequences for forward 
and reverse primers for quantifying CD44 mRNA were 5′-
CGGACACCATGGACAAGTTT-3′ and 5′-GAAAGCCTTGCAGAGGTCAG-3′, 
respectively. The sequences for forward and reverse primers for quantifying VIM 
mRNA were 5′-GCAAAGATTCCACTTTGCGT-3′ and 5′-
GAAATTGCAGGAGGAGATGC-3′, respectively. The housekeeping gene 
Hypoxanthinephophoribosyltransferase-1 (HPRT1) was used as internal reference 
gene for quantification [41] as previously described [42,43]. The expression of RNA 
relative to HPRT1 was calculated [42–44] based on the Ct as R = 2−(ΔCt), where 
ΔCt = Cttarget − CtHPRT1 mRNA gene expression level was reported as 
mean ± standard deviation. 
3.4.6 Alizarin Red S staining and quantification of mineralization 
The cell monolayers were fixed using 4% formaldehyde after washing gently with 
PBS. Alizarin red S staining solution at pH 4.1–4.3 was added to the fixed cell 
monolayers and incubated in the dark for 45 min. Cell monolayers were carefully 
washed with distilled water and PBS after aspirating the remaining alizarin red S 
solution. The stained cells were imaged using a camera (Lumenera Infinity 1) 
mounted on a microscope (Leica DMIL, 0.4 NA and 20 × magnification objective). 
Several images of the stained cells were captured from three independent cultures 
for each stable clone, (each frame capturing more than 50 cells) and the pixels 
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corresponding to alizarin red were quantified and normalized to the total number 
of cells per frame to remove the effects of any differences in cell densities across 
the clones. The pixels corresponding to the alizarin red stained areas were 
identified by their RGB decomposition obtained using MATLAB (Mathworks, Natick, 
MA) and the cells in each frame were counted using the manual mode of Image-J 
software [45]. The colors determined by the criterion R > 180, R > G + 80 and 
B < 100 were found to accurately represent the color of the alizarin red S stain. 
3.4.7 In Vitro migration assays 
Transwell inserts (Costar) with porous polycarbonate membranes with a pore size 
of 8 μm were used to measure the effect of stable OPN silencing on migration in 
MDA-MB-231 cells. shRNA knockdown and control clones (1 × 105 cells) 
suspended in 100 μL of serum-free RPMI were added to the upper chamber of the 
insert and allowed to migrate across the membranes, which occurred under the 
influence of RPMI medium with 5% fetal bovine serum as chemoattractant in the 
lower chamber. After 20 hours, the lower sides of the membranes were fixed in 4% 
formalin and stained with 0.2% crystal violet solution. After staining, four fields of 
view for each insert were obtained with an inverted microscope at 
10 × magnification. Quantitative measurements of the number of cells migrating 
across the membrane were obtained by applying an intensity threshold after 
converting the RBG images to 8-bit grayscale images using Image-J software [45]. 
3.4.8 Experimental animal models: Generation of CTC and LMC 
All animal experiments were approved by the Johns Hopkins University Animal 
Care and Use Program in compliance with the Animal Welfare Act regulations and 
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Public Health Service (PHS) policy. Johns Hopkins University has an approved 
PHS Assurance and maintains accreditation of our program by the Association for 
the Assessment and Accreditation of Laboratory Animal Care (AAALAC) 
International. MDA-MB-231 cells were stably transfected with a construct 
containing DNA of tdTomato fluorescent protein as previously described [43]. 
Stably tdTomato-expressing MDA-MB-231 breast cancer cells (2 × 106) were 
orthotopically implanted into the fourth right mammary fat pad of 6 weeks old 
female athymic nu/nu female mouse (NCI) as described previously [42,43,46]. 
When primary tumor volume reached approximately 500 mm3 after about 8–12 
weeks following inoculation, the mouse was sacrificed, its blood was obtained by 
cardiac puncture, and its lungs were collected to isolate and culture CTC and LMC, 
respectively, as briefly described in the following. For CTC isolation, cardiac 
puncture yielded about 500 μl of blood from each mouse. Red blood cells were 
lysed (ACK lysing buffer, Life technology, Grand Island, NY, USA) and CTCs were 
pelleted by centrifugation, suspended in RPMI 1640 culture medium, and CTC 
presence was verified by fluorescence microscopy of tdTomato-expression in 
MDA-MB-231 cells. For LMC isolation, both lungs were carefully removed and cut 
into 4 mm sized tissue pieces with a sterile scalpel and scissors. These lung tissue 
pieces were placed onto sterile Pyrex petri dishes, washed 3 times in balanced 
salt solution without calcium and magnesium, and finely chopped in 0.25% 
trypsin/EDTA solution. Lung tissue was digested at 37 °C for 1 hour to maximize 
trypsin penetration. Warm, complete media was added to the tissue pieces, which 
was gently dispersed by pipetting. The resulting tissue suspension was then 
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passed twice through a 20 G syringe needle to completely disperse any remaining 
tissue. Two weeks after cell culture of CTC and LMC, the tdTomato-expressing 
CTC or LMC cells were sorted by FACS to clear out all non-fluorescent non-cancer 
cells of lung origin. 
3.4.9 Quantification and statistical analysis 
Statistical significance of the differences between quantitative measurements were 
analyzed by unpaired two-tailed Student’s t-test. P-values < 0.05 were considered 
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Label-free Raman spectroscopy detects stromal adaptations in 
pre-metastatic lungs 
  
Recent advances in animal modeling, imaging technology and functional genomics 
have permitted precise molecular observations of the metastatic process. Yet, a 
comprehensive understanding of the pre-metastatic niche remains elusive owing 
to the limited set of tools that can map subtle differences in molecular mediators in 
organ-specific microenvironments. The challenge of measuring multiple cell types 
in secondary sites, prior to the arrival of metastasizing tumor cells and the 
consequent morphological manifestations, demands non-perturbative analytical 
methods that can offer quantitative biochemical insights. Here we report an 
approach to detect pre-metastatic changes in the lung microenvironment, in 
response to primary breast tumors, using a combination of metastatic mouse 
models, Raman spectroscopy and multivariate analysis of consistent patterns in 
molecular expression. We used tdTomato fluorescent protein expressing MDA-
MB-231 and MCF-7 cells, of high and low metastatic potential respectively, to grow 
orthotopic xenografts in athymic nude mice and allow spontaneous dissemination 
from the primary mammary fat pad tumor. Label-free Raman spectroscopic 
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mapping was employed to record the molecular content of pre-metastatic lungs. 
Our measurements show reliable distinctions in vibrational features, characteristic 
of the collageneous stroma and its cross-linkers as well as proteoglycans, that 
uniquely identify the metastatic potential of the primary tumor by recapitulating the 
compositional changes in the lungs. Consistent with histological assessment of the 
tissue specimen and gene expression analysis, our study suggests that 
remodeling of the extracellular matrix components as indicated by their vibrational 
spectroscopic signatures may present promising markers for objective recognition 
of the pre-metastatic niche, independent of conventional clinical information. 
4.1 Introduction 
While local breast cancers are largely responsive to current therapeutic strategies, 
treatments to permanently eradicate metastasis are yet to be developed. 
Consequently, nearly all breast cancer-related deaths today result from metastatic 
disease that involves distant organs [1]. The distribution of metastases is a non-
random process with each tumor type manifesting a characteristic pattern of 
metastatic involvement in distant vital organs [2, 3]. Stephen Paget’s ‘Seed and 
Soil’ hypothesis originally shifted the attention from a sole focus on the behavior of 
primary tumor cells to the important role of the stroma at the secondary site [4, 5]. 
Seeking to understand the basis of metastasis organotropism, his seminal 
hypothesis postulated that a receptive microenvironment at the secondary organ 
(soil) is crucial to the engraftment of circulating tumor cells (seed). This also 
provided a conceptual framework for later observations in experimental metastasis 
assays that cancer cells derived from a distant site display enhanced metastatic 
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ability to that specific organ [6]. Yet, it is only with recent advances in animal 
metastasis assays, genomic profiling and real-time imaging techniques that the 
molecular components that drive organ-specific metastasis have been specifically 
probed. Translation of the preclinical findings on the metastatic microenvironment 
into a clinical test, however, has not yet been realized.   
Building on the seed and soil hypothesis, emerging evidence suggests the 
formation of a pre-metastatic niche [7, 8], i.e. collective changes at the target 
metastasis sites prior to the arrival of the first tumor cells. This niche development 
in the preferred metastatic sites appears to be driven by soluble growth factors 
secreted by the primary tumor and recruitment of tumor associated cells [9]. The 
priming of the secondary organs was initially attributed to the localization of 
haematopoietic bone marrow progenitor cells expressing vascular epithelial 
growth factor receptor 1 (VEGFR-1) due to VEGF being secreted by the primary 
tumor [7]. Exosomes secreted from primary tumors have also been reported to 
play a significant role in mobilizing these progenitor cells to the pre-metastatic sites 
[10]. The recruitment of tumor-associated cells provides an increased availability 
of chemokines, growth factors, matrix degrading factors and adhesion molecules 
that initiate the metastatic cascade [8, 9]. This process is reported to be 
accompanied by remodeling of the extracellular matrix (ECM) in the pre-metastatic 
niche, notably through the upregulated expression of matrix metalloproteinases 
(MMPs) [11], transformation of local fibroblasts, and focal expression of fibronectin. 
For instance, a recent series of investigations have revealed that lysyl oxidase 
(LOX), an enzyme secreted by hypoxic tumor cells, modulates the ECM in pre-
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metastatic sites by crosslinking collagen fibrils, thereby making it more receptive 
to further myeloid cell infiltration [12, 13].   
While promising, these findings also highlight the need for further research 
to reveal a holistic picture of the pre-metastatic stage that trigger (or inhibit) 
engraftment and proliferation. This, in turn, demands molecular-specific and 
quantitative analytical tools that can provide direct readouts from multiple 
biomolecules without necessitating individual labeling. Such a tool would inform if 
and how the compositional contributors of the stromal microenvironment in 
metastatic sites are changing in response to a spontaneously disseminating 
primary tumor - but prior to the arrival of tumor cells. Vibrational spectroscopy 
offers a promising tool to meet these demands, owing to the wealth of intrinsic 
molecular information (that obviates the need for imaging probes), extensive 
multiplexing capability and facile readout [14-17].  
Spontaneous Raman spectroscopy, in particular, has emerged as an 
attractive technique for the diagnosis of cancers with high specificity and free of 
inter-observer variability [18]. Based on inelastic scattering of light arising from the 
interactions with the tissue being analyzed, Raman spectroscopy affords sub-
cellular signal localization and can easily be extended to in vivo approaches [19, 
20]. Recently, its ability to discern pathologies in advance of their clinical 
manifestations has also been shown [21]. Malins and co-workers elegantly 
demonstrated the early detection sensitivity of vibrational spectroscopy in a study, 
where spectral changes in the DNA of primary tumor were noted 57 days prior to 
the appearance of histological changes [22]. We hypothesized that the utility of 
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Raman spectroscopic information could also be extended to identifying the pre-
metastatic niche, due to the unique structural and chemical changes associated 
with the evolving soil. 
 
 
Figure 4.1: Raman spectroscopic profiling of pre-metastatic lungs. (A) Mouse 
models, orthotopically xenografted with human breast cancer cells of different 
metastatic potential (MCF-7 and MDA-MB-231), were used to study stromal 
adaptations in the lung, prior to seeding of tumor cells. (B) Representative in vivo 
brightfield (left) and fluorescence (right) images of mouse growing a tdTomato-
expressing breast tumor xenograft. (C) Mean Raman spectra (with the shadow 
representing ±1 standard deviation) acquired from lungs of normal mice, and pre-
metastatic lungs of MCF-7 and MDA-MB-231 xenografted mice are shown. 
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Important clues also come from a recent report by Kwak et al., 
demonstrating the utility of infrared (IR) spectroscopic imaging in predicting cancer 
recurrence by exploiting molecular features of the tumor microenvironment [23], 
and our recent observation that lymph nodes in mice with metastatic tumor 
xenografts displayed an increased collagen I density [24]. Consistent with these 
recent literature reports, we suspected that the collagen architectural modifications, 
in part, preceded the seeding of metastatic cancer cells. Because Raman spectra 
report vibrational features characteristic of collagen and its cross-linking moieties 
as well as glycoproteins, our goal in this study was to identify Raman spectral 
patterns that are able to detect characteristic molecular changes in the pre-
metastatic niche.  
Here we have investigated lungs from mouse models that recapitulate 
spontaneously disseminating breast cancer cells of low and high metastatic 
potential, and exploited the molecular basis of Raman spectroscopy to probe the 
pre-metastatic niche (Figure 4.1). Raman spectroscopic mapping measurements 
revealed subtle, but consistent, changes in the vibrational features of ECM 
components of the lungs, in particular in their collagen fiber matrix and 
proteoglycan content. The definition of the pre-metastatic adaptations in spectral 
terms facilitated the development of a decision algorithm, which accurately 
differentiates lungs in mice with metastatic MDA-MB-231 tumor xenografts from 
that in mice with MCF-7 xenografts and normal controls. A continuous model of 
ECM modifications, based on the metastatic potential of the primary tumor, is 
proposed to explain the differential signatures – in the confirmed absence of any 
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tumor cells in the lungs. This model is in agreement with observations from 
Masson’s trichrome staining and gene expression analysis performed on 
microarray data of pre-metastatic lung samples from mice harboring breast tumor 
xenografts. Taken together, this study demonstrates the potential of Raman 
spectroscopy as a rapid, objective and label-free tool in the recognition of pre-
metastatic changes. We envision that our findings here will also accelerate the use 
of Raman spectroscopy in identifying distinct biochemical signatures in organ-
specific niches, thereby enabling a better understanding of organotropism.  
4.2 Materials and Methods 
4.2.1 Tissue preparation and histopathology 
Six-week-old female athymic nu/nu mice (NCI, MD) were orthotopically inoculated 
with 2x106 cells of the human breast cancer cell lines MDA-MB-231 (n=3), or MCF-
7 (n=3) in their fourth right mammary fat pad, as detailed in our previous article 
[25]. For comparison, control mice (n=3) without tumor cell implantation were 
employed in the study. Cell lines were obtained from the American Type Culture 
Collection (ATCC, MD) and stably transfected with a construct containing cDNA of 
tdTomato as described in our previous report [24]. Cell lines tested negative for 
mycoplasma and were authenticated using short tandem repeat (STR) profiling 
prior to inoculation in mice. Cell lines were maintained in RPMI 1640 (Sigma 
Aldrich) supplemented with 10% fetal bovine serum (Sigma Aldrich) and 1% 
penicillin-streptomycin (Sigma Aldrich) in a humidified incubator at 37oC/5% CO2. 
Prior to implantation of MCF-7 cells, mice were supplemented with 17β-Estradiol 
(Innovative Research of America, SE#121, 0.72 mg/pellet, 60 day release) in their 
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neck region [26]. Primary tumor size was monitored, and mice were sacrificed 
within 8-12 weeks of cell implantation when primary tumors grew to ca. 500 mm3 
in volume. Control mice were also sacrificed in this timeframe. Freshly excised 
lungs of mice were cleaned in phosphate buffered saline (PBS) and fixed in 
formalin for 24 hours. Formalin fixed lung tissue samples were rinsed thoroughly 
in excess PBS to remove any residual formalin before acquiring Raman spectra. 
Following spectral acquisition, tissues were stored in 70% ethanol and sent to JHU 
Histology Services for paraffin embedding and serial sectioning, after which one of 
the sections was used for haematoxylin and eosin (H&E) staining. The unstained 
slides were utilized in our laboratory to perform Masson’s trichrome staining for 
collagen as detailed in our previous study [24]. The Institutional Animal Care and 
Use Committee at the Johns Hopkins University School of Medicine approved the 
protocol of this study. 
4.2.2 Acquisition of Raman spectra 
Formalin fixed lung specimens were rinsed in PBS, flattened and placed on a clean 
aluminum block. There was no interference of the tissue Raman spectrum from 
the aluminum substrate, which also ensured a consistent probe-tissue imaging 
distance. A custom-built portable, fiber-probe based Raman spectroscopy system 
was used for spectral acquisition [27]. Briefly, an 830 nm diode laser (500 mW 
maximum power, Process Instruments, Salt Lake City, UT) was used to excite the 
sample. A lensed fiber-optic Raman bundled contact probe (Emvision LLC, FL) 
having a diameter of 2 mm (and an estimated tissue sampling volume of 1 mm3) 
was used to deliver the excitation beam though its central fiber and collect the 
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back-scattered light through an annular ring of optical fibers. The scattered light 
was directed to a spectrograph (Holospec f/1.8i, Kaiser Optical Systems, MI). The 
spectra were then recorded using a thermoelectrically cooled CCD camera (PIXIS 
400BR, 20×20 μm pixels, 1340×400 array, Princeton Instruments, NJ). The laser 
power at the lung tissue samples was maintained at around 15 mW in this study 
and the tissue was kept moist throughout the period of laser exposure by 
intermittent addition of PBS. A total collection time of 10 seconds (10 
accumulations of 1s each to prevent CCD saturation) was used for acquisition of 
each spectrum. Spectroscopic mapping was pursued to overcome the limitations 
of conventional fiber probe-based point spectroscopy that only examines a small 
area of tissue and suffers from undersampling. Wide area mapping, over the entire 
lung specimen, was performed by scanning the optical probe using a pair of 
motorized translation stages (travel range: 13 mm, T-LS13M, Zaber Technologies 
Inc, Vancouver, Canada) in each orthogonal direction. Zaber console (open-
source software) was employed to control the raster scan through the PC serial 
ports. The mapping protocol also ensured the collection of sufficient spectra 
(approx. 300 spectra per mouse) for the development of robust classification 
models.  
4.2.3 Data analysis 
The Raman instrument was wavenumber-calibrated using 4-acetamidophenol 
(Tylenol©) spectra. Raman spectra recorded from mouse lungs were restricted to 
the fingerprint wavenumber region (500-1850 cm-1) for analysis and normalized to 
lie between 0 and 1 in order to remove the effects of potential differences in laser 
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power at the sample. Principal component analysis (PCA) was used to reduce the 
dimensionality of the spectral dataset to a few dimensions characteristic of the 
maximum variance in the dataset [28]. This transformation converts the set of 
spectral recordings into a set of values of linearly uncorrelated variables that form 
an orthogonal basis set. The spectral dataset of each mouse model was subjected 
to PCA using the statistical toolbox of MATLAB 2015b (Mathworks, Natick, MA) to 
obtain principal component (PC) scores and loadings that highlight the spectral 
features characteristic of the class. The use of these key patterns (PCs) enhances 
sensitivity of the analysis by not focusing on small differences in Raman signatures 
that may arise from natural variation or sampling.  
To visualize the differences among the classes, radial visualization maps 
were plotted using the Radviz tool of Orange data mining toolbox [29]. Here we 
utilized the scores of select PCs obtained from subjecting the entire spectral 
dataset to PCA. Guided by the Vizrank algorithm, the PCs were chosen to 
maximize class separation. In the radial visualization plot, the scores of a spectrum 
determine the position of the corresponding data point relative to the PC pivots. 
Partial least squares discriminant analysis (PLS-DA), a supervised classification 
technique based on partial least squares regression, was employed to create 
decision models from the acquired Raman spectra for identifying the pre-
metastatic niche [30]. PLS-DA-derived classification models were built and trained 
using a leave-m-out cross-validation approach that utilizes randomly chosen 
training data consisting of 60% of the data of each class and test data constituted 
by the remaining 40% of the spectra. Randomized equalization of classes was 
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implemented prior to PLS-DA model development to avoid skewing the model 
through disproportionate class sizes. Multiple iterations of class equalization and 
splitting into testing and training sets (10x100) were performed to obtain average 
performance metrics of the PLS-DA derived classification models.  
Collagen quantification of Masson’s trichrome stained tissue slides was 
achieved using FIJI (Image-J based open source software) [31] and MATLAB 
(Mathworks, Natick, MA). The color de-convolution feature provided by FIJI was 
employed to extract an 8-bit frame (dense collagen presence = 0 and no collagen 
presence = 256) corresponding to the color, indicative of collagen content in the 
trichrome stains. The color was defined by average RGB values of pixels in a small 
user-selected region of interest (ROI) chosen in the image. Using in-house 
MATLAB code, the intensity of the pixels was converted to obtain a measure of 
collagen density in each frame. The data was averaged over the entire lung tissue 
section with n>35 fields of view (FOV) per class, where each FOV was ca. 1.75 
mm x 1.33 mm. Statistical significance of differences across the classes was 
evaluated using the Student’s t-test. A conventional criterion of p-value less than 
0.05 was used to consider differences as statistically significant. 
4.2.4 Microarray dataset 
The gene expression microarray dataset GSE62817 from the Gene Expression 
Omnibus (GEO) of the National Center for Biotechnology Information 
(http://www.ncbi.nlm.nih.gov/geo/) was used in this study [32]. This dataset 
contains gene expression data from pre-metastatic lungs of BALB/c mice injected 
with tumor cells into their fourth mammary fat pad. In particular, 67NR (non-
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metastatic) and 4T1 (metastatic) breast carcinoma cell lines were used and lung 
tissue was collected when the tumors reached a volume of 50 mm3. Control mice 
with no tumor cell injections were utilized for comparison. Briefly, RNA was 
extracted using Qiagen kit, and Affymetrix microarrays (Mouse 430-v2) were used 
to analyze the expression profile of tissue samples. The heat map was generated 
using Gene-e matrix visualization and analysis software 
(http://www.broadinstitute.org). We used the moderated F-test statistic for 
selecting relevant genes. Consistent with the number of different groups and 
number of samples per group in the dataset, a threshold F-test statistic of 2.53 
(corresponding to α = 0.125 level of significance) was used. 
4.3 Results and Discussion 
Lung was selected as the target organ in the current pilot study, as it offers a 
favorable site for spontaneous dissemination of breast cancer and is the most 
commonly studied metastatic site in animal models [9, 33]. Primary orthotopic 
MDA-MB-231, and also eventually MCF-7, breast tumor xenografts used in our 
study preferentially metastasize to the lungs [34, 35]. Spectroscopic mapping of 
the lungs, as opposed to a limited number of discrete point measurements, was 
pursued to encompass a large field of view with high spectral contrast. This would 
also account spectroscopically for the intrinsic biological variation in lung tissue 
that could otherwise suppress the subtle differences expected from pre-metastatic 
adaptations. Figure 4.1C shows average Raman spectra recorded from lung 
samples of control mice (‘Control’) as well as mice bearing MCF-7 (‘MCL’) and 
MDA-MB-231 (‘MDL’) tumor xenografts. The spectra shown here were background 
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subtracted for the tissue autofluorescence component. While gross visual 
inspection reveals limited spectral variations, we reason that a subset of pixels 
(representing specific molecular moieties) has predictive power that is lost in 
examining the average value of the spectra across the lung specimen. In an effort 
to focus on elucidating the differentiating biochemical characteristics, we employed 
principal component analysis (PCA). To preserve the subtle spectral features, we 
performed PCA on the normalized spectra recorded from the specimen without 
background subtraction. For comparison, the results obtained following fifth order 
best-fit polynomial based autofluorescence background removal have been also 
been provided alongside (and in Appendix). 
 
 
Figure 4.2: Principal component analysis of the acquired Raman spectra. (A) 
PC loadings derived from spectra of lungs from control mice, i.e. bearing no tumor 
xenograft. (B) PC loadings derived from spectra of lungs belonging to mice bearing 
MCF-7 xenografts (labeled as MCL in the text). (C) PC loadings derived from 
spectra of lungs belonging to mice with MDA-MB-231 xenografts (labeled as MDL 




Consistent differences in Raman spectra reflect biochemical changes in 
pre-metastatic lungs. Figure 4.2 shows the first 7 principal component (PC) 
loadings in order of spectral variance for each of the three classes, Control, MCL 
and MDL. The first few PCs in each class are evidently influenced by the broad 
tissue autofluorescence signal; the characteristic Raman features are more 
prevalent in PCs 4 through 7. The PCs derived from the spectra belonging to the 
lungs of control mice exhibit notable Raman features at 859 cm-1 (C-C stretch of 
proline in collagen), 1003 cm-1 (C–C stretching vibration of the aromatic ring in the 
phenylalanine side chain), 1442 cm-1 (CH2 deformations in lipids), 1592 cm-1 
(tentatively attributed to carbon particles) and 1653 cm-1 (amide-I feature of 
proteins with potential contributions of C=C stretching in lipids) with a weaker peak 
at 1304 cm-1 (in-plane CH2 twisting modes of lipids). These features are 
concordant with prior observations in the literature [36-38]. Table ST4.1 (Appendix) 
lists the prominent peaks observed in the PCs and their characteristic band 
assignments. 
Visual inspection of the PC loadings show an enhancement of the 859 cm-
1 peak, which can be attributed to collagen, for the MDL specimen in comparison 
with MCL and control as well as a new peak at 917 cm-1 (C-C stretch of proline 
ring) [17] for the non-control samples. These spectral differences suggest a 
positive correlation of collagen density in the lung specimens with the presence of 
a primary tumor xenograft and, importantly, with its metastatic potential. Previous 
studies have discussed the role of collagen in the pre-metastatic niche and have 
shown evidence of collagen crosslinking and the creation of a metastatic growth 
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permissive fibrotic microenvironment at secondary sites, which was mediated by 
lysyl oxidase (LOX) secreted by hypoxic tumors [39, 40]. Inhibition of LOX 
synthesis in human breast cancer cells has been shown to reduce the 
accumulation of CD11b+ myeloid cells in pre-metastatic organs of mice with 
orthotopic tumors and prevent metastasis [12]. Another pertinent peak was 
observed at ca. 1061 cm-1 in the MCL and MDL PCs, which is known to be a key 
spectral marker for proteoglycans [41, 42]. This finding offers an intriguing insight 
into the nature of molecular modifications in the pre-metastatic niche, particularly 
in light of the study of Gao et al. This study demonstrated that myeloid cells in pre-
metastatic lungs (recruited by primary tumor derived secretory factors) aberrantly 
expressed versican, an ECM proteoglycan [43]. Versican stimulated mesenchymal 
to epithelial transition of metastatic tumor cells by reducing phospho-Smad2 levels, 
which led to elevated cell proliferation and accelerated metastases. In fact, lung 
metastasis in mouse models was found to be significantly impaired through 
knockdown of versican, reinforcing the importance of proteoglycan content as a 
pre-metastatic site marker. Furthermore, the gradual increase in the prominence 
of proteoglycan marker in PCs with increasing metastatic potential is in agreement 
with the seminal report of Kaplan et al., which showed that recruitment of bone 
marrow-derived cells is correlated to the aggressiveness of the primary tumor [7]. 
On the other hand, a significant suppression of the peaks at ca. 1302 cm-1 and 
1442 cm-1 was noted with a smaller reduction in the intensity of the 1653 cm-1 
feature. Since the former two peaks are characteristic of lipids and the latter also 
has lipid contributions, one can reasonably infer a relative reduction in the lipid 
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Figure 4.3: Visualization of spectroscopic differences due to pre-metastatic 
adaptations. Radial visualization plot showing clusters formed by spectra 
recorded from lung samples of sacrificed mice bearing MDA-MB-231 and MCF-7 
breast cancer xenografts as well as controls without xenografts. 
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Given the large dimensionality of the spectral data, however, it is 
challenging to judge whether the differences across the classes are significant 
from visual inspection of the PC loadings alone. To observe these differences 
better, we employed radial visualization plots that map the scores of multiple PCs 
onto a two-dimensional space for the purpose of clustering. Figure 4.3 shows a 
representative radial visualization plot constructed by using PCs derived from a 
randomized spectral selection with 300 points per class (control, MCL and MDL). 
These were chosen from the total set consisting of ca. 900 spectra/class, which in 
turn were constituted by ca. 300 spectra acquired from spatially distinct points in 
the lung lobes of each mouse. Figure S4.1 (Appendix) shows the corresponding 
radial visualization map after subtraction of tissue autofluorescence background. 
In order to obtain informative projections of the class-labeled data, the 
VizRank algorithm was used to grade the PCs by their ability to visually 
discriminate between classes [44]. Evidently, there are pronounced differences in 
the Raman spectra acquired from lung specimens of control, MCL and MDL mouse 
models, most likely owing to differential priming through factors secreted by the 
primary tumor. The presence of a small overlap of clusters from control and MDL 
mice indicates a limited development of the pre-metastatic niche in some of the 
latter cases and requires further analysis, as detailed in the ensuing paragraphs. 
While the PC score-based plot offers a satisfactory tool for preliminary data 
exploration, it does not provide quantitative information about the potential of 
Raman spectroscopy in recognizing the class (metastatic potential) and in 
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understanding how the lung(s) of an individual mouse responds to the primary 
tumor xenograft. 
Thus, we used partial least squares–discriminant analysis (PLS-DA)-based 
classification models for translating the spectroscopic measurements in the pre-
metastatic lungs to identification of the type of primary tumor xenograft. We 
employed an equal number of spectra belonging to each class (control, MCL and 
MDL) and their class labels to train the classification algorithm. To ensure 
robustness, we evaluated the classifier by testing on a separate validation dataset 
as detailed in the Data Analysis section. Average correct rates of prediction of 
90.1%, 97.7% and 78.4% (95.4%, 95.6% and 75.1% after autofluorescence 
background subtraction) were obtained for the spectra belonging to control, MCL 
and MDL, respectively. The relevant confusion matrix of the reference and 
predicted labels is shown in Table ST4.2 (Appendix). The lower correct 
classification rate for MDL spectra in both the cases is in agreement with the 
overlap of the MDL and control clusters observed on the radial visualization plot in 
Fig. 4.3.  
In order to understand the root cause of the MDL spectra misclassifications, 
we repeated the former analysis by leaving one mouse out of the dataset each 
time (Table 4.1 and Table ST4.3 in Appendix after autofluorescence background 
subtraction). Removing mouse MD #3 (arbitrary numbering of mice used for 
tabulating results) yields near perfect classification accuracy indicating significantly 
lesser pre-metastatic adaptations in the lungs of this animal. Furthermore, 
removing mouse MD #3 also improved the classification rate of spectra belonging 
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to control mice due to enhanced contrast in the training data. Notably, removal of 
any other mouse from the classification protocol did not result in as significant a 
change in the accuracy levels. This reinforces the fact that the improvement 
observed on removal of mouse MD #3 data was not due to overtraining of the 
model on smaller numbers, as otherwise similar enhancements would have been 
noted in all the other cases. The inadequate priming of the MD #3 lungs is also 
supported by application of Chauvenet’s criterion to the set of classification rates 
obtained for the MDL class (Table 4.1). The latter results in designation of MD #3 
as the sole outlier in the group due to its significant deviation from the mean by 
more than the maximum allowable number of standard deviations (max = 1.96 for 
a sample size of n = 10). Application of Chauvenet’s criterion also facilitates 
determination of individual sample eligibility for training the PLS-DA classifier. The 
spectroscopic measurements, thus, capture the inherent variability in metastasis, 
which is commonly regarded as an inefficient process that only a subset of tumor 
cells can successfully navigate [45, 46] and is known to exhibit sporadic 
occurrence across a cohort of animals.  
Finally, we conducted a negative control study to verify that the predictive 
power of the developed algorithms was not driven by potential spurious 
correlations in the spectral dataset [47]. For this validation study, we assigned 
random class labels to the spectra irrespective of their true class origins and 
employed the PLS-DA-derived classification models after similar splitting of the 
data into training and test sets. This resulted in an average correct classification 
rate of 33.3% with a standard deviation of 1.4% (and 33.6% with a standard 
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deviation of 1.4% after background subtraction) for 1000 iterations. The 
significantly low rate of correct classification (consistent with the likelihood of 
random selection of the true class label, 1/3) underscores the absence of chance 
correlations in the developed model. 
 
Table 4.1: Correct classification rates (%) of the PLS-DA-derived model using 
leave-one-mouse-out protocol (MD and MC refer to mouse models with MDA-
MB-231 and MCF-7 tumor xenografts, respectively) 
Mouse 
excluded 
Correct classification rate 
(%) 
Chauvenet’s criterion for 
MDL 
(n = 10; max = 1.96) 
Control MCL MDL  = |xi - xmean|/ Result 
None  90.1 97.7 78.4 0.26 Retain 
MD #1 81.2 97.0 75.7 0.61 Retain 
MD #2 83.8 96.8 76.2 0.54 Retain 
MD #3 100.0 98.6 99.4 2.54 Eliminate 
MC #1 88.8 98.0 78.5 0.24 Retain 
MC #2 89.6 97.3 77.6 0.36 Retain 
MC #3 88.8 98.3 77.3 0.40 Retain 
Control #1 87.2 96.4 73.1 0.96 Retain 
Control #2 92.9 97.3 80.2 0.01 Retain 





Histological assessment of the pre-metastatic niche in mice lungs. Due to 
their high metastatic potential and preference for metastasis to lungs, orthotopic 
MDA-MB-231 xenografts are frequently employed to replicate breast cancer 
metastasis and organotropism [33, 48]. Aggressive subpopulations of MDA-MB-
231 are often derived through multiple rounds of in vivo selection and re-
implantation and have been recently reported to result in macro-metastases to the 
lungs in 100% of all tested mice [35]. In our study, we observed no cancer cell 
seeding in lungs of mice bearing MDA-MB-231 tumor xenografts (time of sacrifice: 
8-12 weeks post orthotopic tumor inoculation). Prior optical tracking studies by 
Winnard and co-workers showed that orthotopically implanted MDA-MB-231 cells 
reached lungs only after ~15 weeks of implantation in SCID mice [34]. They also 
observed the absence of distant metastases after 8 weeks, consistent with the time 
period of sacrifice in our study. MCF-7 cells, often classified as non-metastatic [49], 
were likewise not expected to engraft in the lungs within this 8-12 week time frame. 
However, it is noteworthy that MCF-7 cells are known to eventually metastasize to 
lungs in immunodeficient mice such as NSG [35]. 
Here, the lung tissue sections from each mouse were H&E stained to check 
for the onset (or the lack thereof) of metastasis. Also, to histologically examine the 
differences in collagen content across the classes, serial sections were processed 
with Masson’s trichrome stain. Figure 4.4 shows representative images of H&E 
and Masson’s trichrome stained lung sections belonging to each class (control, 
MCL and MDL). The H&E images corroborate the lack of any metastatic lesions in 




Figure 4.4: Histological assessment of pre-metastatic lungs shows stromal 
changes. Top (A-C) and middle (D-F) panels display representative microscopic 
images of H&E and Masson’s trichrome stained slides at 5x and 10x 
magnifications, respectively. The H&E stained sections confirm the absence of 
tumor cell seeding in the lungs of controls. Masson’s trichrome stain delineates 
collagen fibers in the extracellular matrix and is quantified through image 
processing, as shown in the bottom panel (G-I). The left (A, D, G) panel shows 
lung sections derived from control mice whereas the middle (B, E, H) and right (C, 
F, I) panels represent lung sections from mice bearing MCF-7 (non-metastatic) and 
MDA-MB-231 (metastatic) tumor xenografts, respectively. The scale bars in the 





Figure 4.5: Quantification of collagen fiber density in pre-metastatic lungs. 
(A) Bar plot showing mean and standard deviation of collagen density across the 
three classes (with all mice included) along with pairwise Student’s t-test p-values. 
(B) Bar plot showing mean and standard deviation of collagen content across the 
three classes (after exclusion of MDA-MB-231 xenograft bearing mouse displaying 
atypical Raman data) along with pairwise Student’s t-test p-values. 
 
The Masson’s trichrome stained sections were used for quantification of the 
mean collagen density for each class (detailed in Materials and Methods). Figure 
4.5A shows the mean bar plot that highlights the differences in collagen density 
for control mice and mice bearing MCF-7 and MDA-MB-231 xenografts. We 
observe that the metastatic potential of the primary tumor is positively correlated 
with the collagen density in the pre-metastatic niche. Yet, the differences in the 
mean collagen density values between MCL and MDL samples do not reach 
statistical significance (p<0.05). Based on our spectroscopic findings, we 
suspected that the lung specimens of mouse MD #3 may possibly skew the 
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collagen density values of the MDL set. Accordingly, we re-calculated the values 
by removing the images of the lungs of this mouse, as shown in Fig. 4.5B. With 
this modification, the differences among each pair of classes were found to be 
statistically significant. This improvement of contrast in collagen density 
corresponds well with our spectroscopic findings and reflects the biochemical 
sensitivity of the vibrational spectroscopic data. 
  In light of the spectroscopic identification of stromal adaptations, we further 
sought to investigate the genetic underpinnings of pre-metastatic priming of lungs. 
We performed gene expression analysis on publicly available microarray data 
(GSE 62817) to determine markers in pre-metastatic lungs in response to primary 
breast tumors of divergent metastatic potential [32]. Specifically, the data included 
gene expression levels corresponding to the lungs of normal mice (n=5) as well as 
pre-metastatic lungs of mice injected with non-metastatic 67NR breast carcinoma 
cells (n=5) and with metastatic 4T1 breast carcinoma cells (n=4). Seeking to isolate 
genes relevant to our study, we restricted our search to genes encoding for key 
stromal constituents and significantly overexpressed in pre-metastatic lungs of 4T1 
tumor bearing mice. Figure 4.6 shows the heatmap representing expression levels 
of these genes along with corresponding moderated F-statistic. Pre-metastatic 
lungs of the 4T1 tumor bearing mice demonstrate a selective upregulation of genes 
related to ECM constituents, notably collagen, fibronectin, versican and glypican. 
Importantly, each of these ECM components exhibits a decreasing gradient of 
values from 4T1 to 67NR and then to control cases. The differential expression of 
stromal genes in response to primary tumor development can, thus, help explain 
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our observations of discernible biochemical alterations in pre-metastatic lungs of 
mice bearing MCF-7 xenografts, even though these cells rarely metastasize in the 
mouse model used. 
 
 
Figure 4.6. Gene expression changes in pre-metastatic lungs as a function 
of metastatic potential of primary tumor. Microarray gene expression data heat 
map was obtained by analyzing the publicly available dataset GSE62816 on the 
Gene-e data visualization and analysis platform. The sample cohort includes lungs 
of mice bearing breast tumor xenografts of different metastatic potential. Total RNA 
was isolated from the pre-metastatic lungs and hybridized on an Affymetrix Mouse 
Genome 430 2.0 Array. Genes that are relevant to spectral markers identified in 
the current study and overexpressed in response to the metastatic potential of the 
primary tumor were analyzed. Moderated F-value of 2.53 was set as the criterion 
for inclusion. 
 
 Taken together, our findings suggest that remodeling of the ECM such as 
an increase in collagen and proteoglycan content occurs in response to primary 
tumor derived factors, which precedes the actual seeding of tumor cells at the 
distant metastatic site. The data in this study support a continuous pre-metastatic 
niche formation model from primary tumors with low and high metastatic potential, 
rather than discrete pre-metastatic adaptations that are representative of the highly 
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metastatic model alone. This would also imply that pre-metastatic adaptations are 
a necessary condition for further progression but not predictive of the eventual 
success of metastases. 
In conclusion, the current study proposes Raman spectroscopy as a label-
free molecular-specific tool for detection of pre-metastatic adaptations in the 
stromal environment. Using breast cancer metastasis to the lungs as the paradigm, 
we have demonstrated that Raman spectroscopy accurately detects changes in 
the ECM of pre-metastatic lungs, which correlate with the metastatic potential of 
the respective primary tumor xenograft. We identified spectral markers 
corresponding to collagen and proteoglycan that offer molecular insights into the 
formation of the pre-metastatic niche while also facilitating objective detection. The 
data presented here are unique and complementary to other microenvironment 
profiling methods such as genomic assays and mass spectrometry. While breast 
cancer metastasis to the lungs has been chosen for the current study, it should be 
noted that this approach can be extended to study the development of pre-
metastatic niches at any secondary target organ from primary breast and non-
breast malignancies.  
We envision that the use of Raman spectroscopic imaging in conjunction 
with further biochemical assays will offer detailed mechanistic insights into pre-
metastatic niche formation and evolution. As such, this offers a unique research 
tool that combines microenvironment and cellular profiling through non-
perturbative, multiplexed measurements of proteins, nucleic acids, lipids and 
metabolites. Building on the ability to detect such subtle changes in tissue 
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composition, and as discussed in recent reports [18, 23], we anticipate that Raman 
spectroscopic imaging can, with further refinement, facilitate surgical margin 
assessment in tissue conserving surgery and provide prediction of tumor 
recurrence. Integration of Raman spectroscopy with minimally invasive biopsy 





Table ST4.1: Band assignment for spectral features observed in PC loadings 
derived from the Raman spectra of the mouse lungs 
Observed Raman 
Peaks in the PC 
loadings (cm-1) 
Raman band assignment from literature 
859 C-C stretch of proline (Collagen) 
917 C-C stretch of proline ring (Collagen) 
1003 
C–C stretching vibration of the aromatic ring in the 
phenylalanine side chain (Collagen) 
1061 OSO3 symmetric stretching (Proteoglycans) 
1304 In-plane CH2 twisting modes of lipids 
1442 CH2 deformation of lipids 
1592 Carbon particles (source of particles unknown) 
1653 
Amide I (symmetric C=O stretching mode of proteins) 
and C=C lipid stretch (Lipids and proteins) 
 
Table ST4.2: Confusion matrix for PLS-DA derived classification model 
showing correct classification rates (%, averaged over 1000 iterations) 
 Predicted Class Labels 
 
 

















90.1 0.1 9.8 
MCL 1.0 97.7 1.3 




Table ST4.3: Correct classification rates (%) of the PLS-DA-derived model 
using leave-one-mouse-out protocol with background subtracted spectra 




Correct classification rate 
(%) 
Chauvenet’s criterion for 
MDL 
(n = 10; max = 1.96) 
Control MCL MDL  = |xi - xmean|/ Result 
None  95.4 95.6 75.1 0.71 Retain 
MD #1 85.7 94.2 81.5 0.04 Retain 
MD #2 90.1 94.8 76.8 0.52 Retain 
MD #3 100.0 96.0 100.0 2.18 Eliminate 
MC #1 88.5 96.3 83.0 0.21 Retain 
MC #2 96.3 95.5 74.5 0.77 Retain 
MC #3 96.2 96.5 73.1 0.95 Retain 
Control #1 96.7 93.4 73.7 0.87 Retain 
Control #2 98.0 94.0 84.8 0.42 Retain 





Figure S4.1: Radial visualization plot after background subtraction. Radial 
visualization plot showing clusters formed by spectra recorded from lung samples 
of sacrificed mice bearing MDA-MB-231 and MCF-7 breast cancer xenografts as 
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Label-free Raman spectroscopy reveals signatures of radiation 
resistance in the tumor microenvironment 
  
Delay in the assessment of tumor response to radiation therapy continues to pose 
a major challenge to quality of life for patients with non-responsive tumors. Here 
we exploited label-free Raman spectroscopic mapping to elucidate radiation-
induced biomolecular changes in tumors and uncovered latent microenvironmental 
differences between treatment-resistant and -sensitive tumors. We used isogenic 
radiation-resistant and -sensitive A549 human lung cancer cells human head and 
neck squamous cell carcinoma (HNSCC) cell lines (UM-SCC-47 and UM-SCC-
22B, respectively) to grow tumor xenografts in athymic nude mice and 
demonstrated the molecular specificity and quantitative nature of Raman 
spectroscopic tissue assessments. Raman spectra obtained from untreated and 
treated tumors were subjected to chemometric analysis using multivariate curve 
resolution-alternating least squares (MCR-ALS) and support vector machine (SVM) 
to quantify biomolecular differences in the tumor microenvironment. The Raman 
measurements revealed significant and reliable differences in lipid and collagen 
content post-radiation in the tumor microenvironment, with consistently greater 
changes observed in the radiation-sensitive tumors. In addition to accurately 
 
This chapter is a reprint of the peer-reviewed publication: Paidi SK*, Diaz PM*, Dadgar S*, Jenkins 
SV, Quick CM, Griffin RJ, Dings RPM, Rajaram N, Barman I. “Label-free Raman spectroscopy 
reveals tumor microenvironmental signatures of radiation resistance” Cancer Research, 79(8), 
2054-64, 2019. (* denotes equal contribution) 
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evaluating tumor response to therapy, the combination of Raman spectral markers 
potentially offers a route to predicting response in untreated tumors prior to 
commencing treatment. Combined with its non-invasive nature, our findings 
provide a rationale for in vivo studies using Raman spectroscopy, with the ultimate 
goal of clinical translation for patient stratification and guiding adaptation of 
radiotherapy during the course of treatment. 
5.1 Introduction 
Radiation in conjunction with chemotherapy or other targeted therapies is used to 
treat the majority of lung and head and neck cancer patients. The overall radiation 
dose is fractionated and delivered over a period of 5-7 weeks (2 Gy/day, 5 
days/week) because dose fractionation is believed to improve tumor oxygenation 
and, hence, overall cell kill [1, 2]. An outstanding challenge in optimizing the 
efficacy of such treatment resides in determining the degree of radiosensitivity 
associated with a specific patient’s disease and the extent of tumor response to 
radiation. There are no accepted methods to determine treatment response either 
before or during the early stages of therapy. Although Human Papilloma Virus 
(HPV)-negative head and neck squamous cell carcinomas (HNSCCs) are 
associated with significantly worse outcomes compared with HPV-positive tumors 
[3, 4], HPV status is not used to guide treatment of HNSCC. Currently, X-ray 
Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) is used to 
determine tumor shrinkage about 2-3 weeks after completion of therapy. Positron 
Emission Tomography (PET) of fluorodeoxyglucose (FDG) uptake to measure 
functional tumor response is recommended about 8-12 weeks after completion of 
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therapy to avoid false positives. Hence, patients who undergo the full treatment 
regimen and are later identified as non-responders are exposed to the toxic side 
effects of ineffective therapy for the full duration of the treatment regimen. 
Identifying patients with radiation-resistant tumors, prior to commencing treatment 
or immediately after, would significantly improve treatment response rates and 
help non-responding patients avoid the toxic side effects of ineffective radiation 
therapy.  
Seeking to address this unmet need, molecular alterations in the tumor 
microenvironment in response to radiation therapy have been studied from multiple 
points of view including tumor hypoxia [5-7], cell repopulation [8-10], and genetic 
mutations involved in DNA repair pathways [11]. However, elucidation of serum 
and/or imaging biomarkers for accurate patient stratification and continuous 
assessment of therapy response, and their translation to the clinic has proven to 
be challenging. In an effort to develop better phenotypic strategies that could aid 
the clinical practice of radiation oncology, we propose an entirely complementary 
optical tool to the existing imaging arsenal featuring Raman scattering to non-
invasively quantify the putative differences in the molecular milieu of radiosensitive 
and radioresistant tumors. 
 Raman spectroscopy offers a non-ionizing, label-free and highly specific 
technique for molecular characterization of the tumor and its microenvironment [12, 
13]. It relies on the inelastic scattering of light, arising from its interactions with the 
biological specimen, to quantify the unique vibrational modes of molecules within 
its native context [14]. Raman spectroscopy offers the ability to probe biomolecular 
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changes both in vivo and ex vivo, and interrogate complex molecular heterogeneity 
directly from cells and tissues [15]. Recent studies by us and others have 
harnessed vibrational profiles for objective recognition of epithelial and stromal 
changes in cancers [16-22]. Emerging data suggests the presence of post-
radiation alterations in Raman spectral features and biomolecular differences 
between cell lines of varying radiosensitivity [23, 24]. Krishna and colleagues 
showed that radiation-induced changes in Raman spectra could be used to 
differentiate treatment responders and non-responders in excised cervical cancers; 
however, pre-treatment Raman spectra were incapable of identifying radiation 
response [25]. Furthermore, a recent Raman spectroscopic study on ex vivo tumor 
xenografts by Jirasek and co-workers identified elevated levels of glycogen in 
tumors exposed to a single, high radiation dose of 15 Gy [26]. While these reports 
underscore the promise of Raman spectroscopy in detecting radiation-induced 
changes, these measurements were performed on cells or tumor xenografts 
following a single radiation dose. More systematic studies that examine the 
sensitivity of Raman spectroscopy to changes in the tumor microenvironment 
when subjected to fractionated, clinically relevant radiation doses have been 
lacking. Such measurements would provide a better understanding of molecular 
modifications resulting from fractionated dosing and, ultimately, facilitate a 
personalized treatment approach. In addition, spectral markers of intrinsic 
radiation resistance that can be identified in tumors even before commencing 
therapy could provide a paradigm shift in determining treatment regimen.  
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 The goal of our study was to leverage Raman spectroscopy to investigate 
biomolecular changes within tumor xenografts in response to fractionated radiation 
therapy, and to determine the feasibility of differentiating treatment response from 
failure. Additionally, we sought to determine whether classifier models based on 
Raman spectral markers could be used to distinguish between untreated radiation-
resistant and sensitive tumors. To accomplish our goals, we used two sets of 
radiation-sensitive and radiation-resistant cell lines. First, we employed a recently 
developed matched model of radiation resistance [27], wherein a radiation-
resistant clonal population of cells (rA549) was generated from parental A549 lung 
cancer cells. Second, we used HNSCC cell lines – UM-SCC-22B (UM22) and UM-
SCC-47 (UM47) – for which radiation resistance and sensitivity have been 
established in previous studies [28]. Raman spectroscopic mapping of excised 
tumor xenografts (control and radiated tumors) grown from all four cell lines 
revealed consistent compositional alterations based on tumor type and in response 
to a radiation dose of only 2 Gy. Using multivariate curve resolution-alternating 
least squares (MCR-ALS), we translated the spectral information to uncover 
changes in lipid, collagen, and glycogen content. Data from both lung and head 
and neck (henceforth referred to as HN) tumors show consistently higher changes 
in lipid and collagen content in radiation-sensitive tumors that were treated with 
radiation compared with their radiation-resistant counterparts. Definition of the 
tumor phenotypes in terms of quantitative spectral features corresponding to key 
biomolecules also enabled the development of classifier models that exhibit high 
accuracy in discriminating between radiation-resistant and sensitive tumors. 
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Furthermore, our use of an isogenic radiation-resistant clone allowed, to the best 
of our knowledge, the first determination of discriminative Raman features in 
untreated tumors thereby offering fresh insights into specific molecular roles 
underlying intrinsic radiation resistance. Taken together, our findings highlight the 
potential of Raman spectroscopic imaging as a label-free, non-ionizing tool whose 
in vivo translation would permit monitoring of therapeutic effects with finer temporal 
resolution than is possible at the present time and potentially enable stratification 




Figure 5.1: Raman spectroscopic study of radiation response and resistance. 
Overview of the (A) experimental and (B) data analysis workflow for Raman 
spectroscopic mapping in lung and head and neck tumor xenografts, of differential 
intrinsic radioresistance, subjected to radiation therapy. Details of the individual 




5.2 Materials and Methods 
5.2.1 Cell culture 
Human lung carcinoma A549 cells were purchased from American Type Culture 
Collection (ATCC; CCL185) and were authenticated using short tandem repeat 
(STR) profiling. A549 cells were grown in Ham’s F-12K (Kaighn’s) Medium mixed 
with 10% (v/v) fetal bovine serum and 1% (v/v) penicillin-streptomycin. These cells 
were irradiated at an average dose of 2.2 Gy every three days using an 
orthovoltage X-ray irradiator (CP-160, Faxitron X-Ray Corp. Wheeling, IL) for a 
cumulative dose of 55 Gy (25 fractions) to create the radiation-resistant cell clones 
(rA549) [27]. UM-SCC-22B and UM-SCC-47 were purchased from EMD Millipore 
and cultured in a mixture of Dulbecco’s Modified Eagle Medium (DMEM), 10% 
Fetal Bovine Serum (FBS), 1% Penicillin-Streptomycin, 1% non-essential amino 
acids (NEAA), and 1% L-Glutamine. All cell lines used in this study tested negative 
for mycoplasma and were authenticated using short tandem repeat (STR) profiling. 
Fractionated therapy of tumor xenografts. A schematic representation of 
this study design is presented in Fig. 5.1A. All animal studies were approved by 
the Institutional Animal Care and Use Committee (IACUC) at the University of 
Arkansas (Protocols 16022 and 18061). Athymic nu/nu mice were injected with a 
subcutaneous bolus of cells suspended in 100 µl of serum and media-free saline 
(10 million for A549 and rA549 cells, 2 million for UM-SCC-22B and UM-SCC-47) 
to grow tumor xenografts. Once tumor volume reached 200 mm3, mice were 
randomized to either radiation (XT) or control (NT) groups, as presented in Table 
5.1. Fractionated radiation therapy was administered using an X-RAD 320 
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biological irradiator (Precision X-Ray, North Branford, CT) as four 2 Gy fractions 
delivered over two consecutive weeks (total dose of 8 Gy), as described by others 
[28]. All animals completed the treatment. Tumor volumes were monitored using 
Vernier calipers, and tumors were excised when the majority of untreated control 
tumors had reached 1500 mm3 (approx. 35-50 days after treatment commenced). 
Tumor volume was calculated according to the equation V = (π/6) x (length) x 
(width) x (height). A comparison of tumor xenograft volumes is presented in Fig. 
SF1. After excision, tumors were embedded in OCT mounting medium, snap-
frozen, and stored at -80 oC. 
Table 5.1: Cell lines used to generate tumor xenografts in the study 
Lung Tumors Head and neck tumors 
Tumor group Class label 
Number 
of tumors 
Tumor group Class label 
Number 
of tumors 
A549-NT A549-NT 5 UM-SCC-22B-NT UM22-NT 6 
A549-XT A549-XT 4 UM-SCC-22B-XT UM22-XT 7 
rA549-NT rA549-NT 5 UM-SCC-47-NT UM47-NT 9 
rA549-XT rA549-XT 5 UM-SCC-47-XT UM47-XT 10 
Total number of tumors 19 Total number of tumors 32 
 
5.2.2 Raman spectroscopy 
The frozen tumors were thawed and fixed in 10% neutral buffered formalin prior to 
making Raman measurements. The fixed tumors were rinsed in PBS and 
sandwiched between a quartz cover slip and aluminum block to maintain a 
constant distance between the tissue and probe. The flattened tumors were 
scanned using a fiber-optic probe-based portable Raman spectroscopy system [16, 
29]. Briefly, the custom-built system consists of an 830 nm diode laser (500 mW 
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maximum power, Process Instruments) as the excitation source, and a 
combination of a spectrograph (Holospec f/1.8i, Kaiser Optical Systems) and a 
thermoelectrically (TE)-cooled CCD camera (PIXIS 400BR, Princeton Instruments) 
for recording spectra. Laser delivery and collection of back-scattered light was 
achieved via a lensed fiber-optic bundled Raman probe (probe diameter: 2 mm; 
Emvision LLC) with an estimated tissue sampling volume of 1 mm3. The laser 
power at the tumor samples was maintained at ~ 20 mW in this study. Acquisition 
time for each spectrum was 10s (10 accumulations of 1 second each to prevent 
saturation of CCD). Tissue dehydration due to laser exposure was prevented by 
intermittent addition of PBS. Raster scanning of the probe using motorized 
translation stages (T-LS13M, Zaber Technologies Inc., travel range: 13 mm) and 
spectral acquisition were performed on each side of the flattened tumors (~ 100 
mm2) using a LabVIEW interface. About 4100 and 7000 spectra were acquired 
from the nineteen lung and thirty-two HN tumor xenografts, respectively.  
5.2.3 Data analysis  
Figure 5.1B illustrates the data analysis workflow in this study. All the data 
analysis in the present study was carried out using scripts written in MATLAB 
2017a (Mathworks, Natick, MA, USA) environment unless otherwise stated. The 
wavenumber axis of the Raman system was calibrated using 4-acetamidophenol. 
The fingerprint wavenumber region (600 - 1800 cm-1) was chosen for further 
analysis. The Raman spectra recorded from the tumors were subjected to a fifth 
order best-fit polynomial-based fluorescence removal and cosmic ray removal 
using median filtering. The spectra were then vector normalized (such that their 
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Euclidean norm is set to unity) to minimize the effects of potential variations in laser 
power at the sample. The normalized spectra were used without any spatial 
averaging in the analysis. Multivariate curve resolution - alternating least squares 
(MCR-ALS) was employed to recover the pure spectral profiles of the chemical 
constituents of the tissue specimen without a priori information of the composition 
of the specimen [30]. The decomposition is achieved through an iterative 
optimization routine under non-negativity constraint on pure spectral (loadings) 
and concentration (scores) matrices. The non-negativity constraints enable us to 
interpret the unresolved specimen spectra in the form of loadings that represent 
spectra of pure (or enriched) biochemical components and the corresponding 
scores that provide a measure of abundance of the particular component. 
Additionally, spectral equal length constraint is imposed on the pure spectra to 
facilitate comparison of corresponding scores across the classes (treatment 
groups). The normalized scores corresponding to each key biological constituent 
were compared across different classes through box and whisker plots with 
conventional thresholds. The spatial heterogeneity in the score maps of major 
biological constituents for each tumor was quantified in terms of distributional 
homogeneity index (DHI), as defined elsewhere in the literature [31]. The 
significance of differences in medians of constituent scores across studied classes 
were assessed based on two-sided Wilcoxon rank sum test statistics. A 
conventional criterion of p-value less than 0.05 was used to consider the medians 
different. The differences between the groups were quantified in terms of effect 
size calculated using the Wendt formula for rank biserial correlation [32]. 
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 Support vector machine (SVM) was used to develop a decision algorithm to 
identify radiation treatment response and to predict resistant phenotype prior to 
treatment. SVM is a nonlinear classification method wherein classification is 
achieved by solving a constrained quadratic optimization problem to obtain 
separating boundaries between the classes in higher dimensional spaces [33]. In 
this study, the LIBSVM library [34] was used to develop a C-SVM classifier. The 
background-corrected spectra were used along with tumor group labels for each 
group studied, without any spatial averaging. A radial basis function kernel with a 
Gaussian envelope was employed to enable nonlinear mapping of the input feature 
space, and the optimal C-SVM parameters (i.e. cost and kernel parameter gamma) 
were selected using a k-fold cross validation-based grid search algorithm. A leave-
one-mouse-out analysis was conducted in which spatially distinct spectra 
belonging to each mouse were eliminated from the training dataset and the 
resulting binary SVM classifiers for pairs of classes of interest were tested using 
the spectra belonging to the left-out mouse. Each mouse specimen was assigned 
an overall predicted class label if more than 90% of its spectra were predicted as 
belonging to that class; otherwise, the specimen was labeled as unclassified if the 
desired confidence level was not achieved. Randomized class equalization was 
performed iteratively prior to implementing SVM classification in order to avoid 
skewing the model due to varying class sizes. 
5.2.4 Histopathology  
The tumors were stored in 70% ethanol after acquisition of Raman spectra and 
submitted to the Phenotyping and Pathology Core at Johns Hopkins Medical 
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Institutions. The formalin-fixed tumors were embedded in paraffin and sectioned 
serially onto glass slides for histology. Hematoxylin and eosin (H&E) staining, 
Masson’s trichrome staining for collagen and Periodic acid Schiff (PAS) staining 
(without Hematoxylin counterstain) for glycogen were performed by the Core 
according to standard protocols. The stained slides were imaged using a Leica 
DMi8 inverted optical microscope. In addition, Oil Red O staining for lipids was 
performed on frozen tumor sections according to standard IHC protocols and 
imaged using a Nikon fluorescence microscope.  
5.3 Results 
To capture the tumor heterogeneity and variance arising from differential response 
to treatment, lung and HN tumors in each group – radiation treated (XT) and 
controls (NT), were mapped to obtain spatially distinct Raman spectra from each 
specimen (Fig. 5.2A). Each map had an average of 218 spectra (ranging between 
50 and 334 spectra depending on the size of the tumor). Except for this 
visualization (Fig. 5.2A), the spectra collected from each tumor specimen were 
treated individually without any spatial averaging in all analyses. The spectra 
across all the classes show prominent peaks at 1045 cm-1 (glycogen), 1256 cm-1 
(glycogen), 1301 cm-1 (CH vibration in lipids), 1448 cm-1 (CH2 bending modes in 
lipids and collagen), and 1656 cm-1 (amide-I feature of proteins with potential 
contribution from C=C stretching in lipids). To discern possible molecular 
differences, the spectral datasets were decomposed into key compositional 
biomolecular signatures that were compared across the different groups.  
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To achieve this decomposition, we performed MCR-ALS with 7 components to 
obtain a loadings matrix containing the ‘pure component’ basis spectra and a 
scores matrix containing the weights of each of the seven components for all the 
spectra in the dataset. Figures 5.2B and 5.2C illustrate the relevant MCR loadings 
that present Raman features corresponding to key tissue constituents in the lung 
and HN tumor cohorts, respectively. The remaining loadings, that do not show 
direct correspondence to the vibrational signature of a prominent molecular 
constituent or stem from the presence of formalin (spectral contaminant in the 
tissue specimen), are provided in the Fig. S5.2 (Appendix). As seen in Fig. 5.2B, 
spectrum B1 shows prominent peaks at 1078 cm-1, 1266 cm-1, 1301 cm-1, 1442 
cm-1 and 1654 cm-1 that are characteristic of lipids, specifically triglycerides. 
Spectral pattern B2 resembles the Raman spectral profile of glycogen with peaks 
at 708 cm-1, 940 cm-1, 1044 cm-1, 1078 cm-1 and 1256 cm-1. Furthermore, B3 has 
spectral features corresponding to nucleic acids at 790 cm-1, 812 cm-1 and 1082 
cm-1, while loading B4 has peaks at 851 cm-1, 928 cm-1, 1040 cm-1, 1251 cm-1, 
1315 cm-1, 1453 cm-1 and 1661 cm-1, which are characteristic of collagen. The 
loadings derived from the HN tumor dataset C1, C2 and C3 presented features 
similar to the loadings B1, B3 and B4, respectively. The detailed peak allocations 
of all the features of the 7 loadings derived from lung and HN tumor datasets have 
been tabulated in Tables ST5.1 and ST5.2 (Appendix), respectively. It is worth 
noting that the MCR decomposition of HN tumors did not reveal a glycogen-rich 
loading. The minor spectral features that stem from the use of formalin as a fixative 
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– at 1490 cm-1 and 1040 cm-1 – present themselves in a single MCR loading, thus 
indicating that the effects of formalin fixation may be digitally removed [35]. 
 
Figure 5.2: Raman spectra of radiation-resistant and sensitive tumors. (A) 
Mean Raman spectra (with the shadow representing 1 standard deviation) 
acquired from lung tumors derived from parental A549 and radiation-resistant 
(rA549) cells and head and neck tumors derived from radiation-sensitive UM-SCC-
22B and radiation-resistant UM-SCC-47 cells. Each of the types were either 
exposed to fractionated radiation (XT) or sham radiation (NT). (B) A subset of 
relevant MCR loading vectors derived from the spectra of lung tumors belonging 
to all the four study classes. The spectra B1 through B4 represent lipid-rich, 
glycogen-rich, nucleic acid-rich and collagen-rich loadings, respectively. (C) A 
subset of relevant MCR loading vectors derived from the spectra of tumors 
belonging to head and neck tumor dataset. The spectra C1 through C3 represent 
lipid-rich, nucleic acid-rich and collagen-rich loadings, respectively. 
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Representative MCR score maps (abundance maps) of the observed 
relevant loadings across the treatment groups have been provided in Fig. S5.3 
(Appendix). To characterize the spatial heterogeneity in biochemical composition 
of the studied tumors, we measured the distributional homogeneity index (DHI) for 
each MCR score map. DHI is a measure of deviation of the spatial distribution in 
compositional maps from their randomized counterparts [31]. Thus, DHI is 
positively correlated with heterogeneity in abundance maps, with a value of one 
representing homogeneous (or randomized) distribution and higher values 
indicative of localization of constituents. Therefore, from the observed large values 
of DHI (Fig. S5.3), it is evident that the abundance maps for relevant loadings 
obtained for lung and HN tumors exhibit substantial spatial heterogeneity in the 
tumor samples. 
 The primary objectives of our study were to investigate differences in 
radiation-induced microenvironmental changes between resistant and sensitive 
tumors, and whether such molecular alterations were consistent in tumors derived 
from two different sites – lung and HN. Accordingly, NT vs. XT comparisons for 
each of the 4 cell lines were performed to evaluate the differential response of 
sensitive (A549, UM-SCC-22B) and resistant (rA549, UM-SCC-47) tumors. A 
secondary objective was to determine if these molecular features could distinguish 
between untreated resistant and sensitive tumors. Since the HN tumors stemmed 
from different cell lines, this specific comparison was only performed in the lung 
cohort (A549-NT vs rA549-NT) to identify intrinsic differences underlying radiation 
resistance. Here, we used density scatter plots as they allow better visualization 
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of large datasets by avoiding overlap in regions of high density. Figures 5.3A-C 
present three-dimensional (3D) density plots using the normalized MCR-ALS 
scores corresponding to the lipid-rich, glycogen-rich and collagen-rich loadings of 
A549 and rA549 tumors. Similarly, two-dimensional (2D) density plots with only 
lipid-rich and collagen-rich loadings are shown in Figs. 5.3D-E for the HN tumors. 
Both sets of density plots underscore expected tumor heterogeneity and critically, 
the presence of group-specific local spectral clustering, which is reflected in the 






Figure 5.3: Qualitative visualization of MCR-ALS scores of Raman spectra. 
(A-C) Three-dimensional density plots showing the distribution of normalized 
scores of lipid-rich, collagen-rich and glycogen-rich MCR-ALS loadings showing 
radiation induced differences in sensitive lung tumors (A549-NT vs A549-XT), 
radiation induced differences in resistant lung tumors (rA549-NT vs rA549-XT) and 
pre-radiation differences between sensitive and resistant lung tumors (A549-NT vs 
rA549-NT), respectively. (D-E) Two-dimensional density plots showing the 
distribution of normalized scores of lipid-rich and collagen-rich MCR-ALS loadings 
showing radiation induced differences in sensitive head and neck tumors (UM22-
NT vs UM22-XT) and radiation induced differences in resistant head and neck 
tumors (UM47-NT vs UM47-XT), respectively. The class specific clustering in high 




To quantitatively study the differences across the treatment groups, we 
compared the normalized MCR-ALS scores of lipid-rich, collagen-rich and 
glycogen-rich loadings. We observed an increase in lipid, collagen, and glycogen 
levels for both sensitive (Fig. 5.4A) and resistant (Fig. 5.4B) lung tumors that were 
treated with radiation, with a much larger increase in the lipid-rich and collagen-
rich signatures in the radiation-sensitive tumors. To examine intrinsic 
radioresistance, we also compared the scores of these biomolecular components 
between untreated A549 and rA549 tumors (Fig. 5.4C). The MCR-ALS scores 
point to higher lipid and collagen content but lower glycogen content in the resistant 
tumors compared with the sensitive tumors. Furthermore, we observed very similar 
effects in the HN tumors with a greater increase in lipid and collagen levels in the 
radiation-sensitive UM-SCC-22B (Fig. 5.4D) compared to the radiation-resistant 
UM-SCC-47 tumors (Fig. 5.4E). Glycogen, as mentioned previously, was not 
observed as a significant feature in the HN tumors. Notably, the greater changes 
in sensitive tumors post-radiation are also borne out by the effect sizes for lipid 
and collagen content, which are consistently higher for the sensitive tumor cohorts 






Figure 5.4: Quantitative MCR-ALS analysis of Raman spectra. (A-C) Boxplots 
of normalized scores of lipid-rich, collagen-rich and glycogen-rich MCR-ALS 
loadings showing radiation induced differences in sensitive lung tumors (A549-NT 
vs A549-XT), radiation induced differences in resistant lung tumors (rA549-NT vs 
rA549-XT) and pre-radiation differences between sensitive and resistant lung 
tumors (A549-NT vs rA549-NT), respectively. The differences in the scores of lipid 
and glycogen loadings are statistically significant (indicated by * and n.s. otherwise) 
at p < 0.001 level (Wilcoxon rank sum test) for each of the three comparisons (A-
C), whereas the differences in the scores of collagen loadings are statistically 
significant only for the comparisons in (A) and (C). (D-E) Boxplots of normalized 
scores of lipid-rich and collagen-rich MCR-ALS loadings showing radiation induced 
differences in sensitive head and neck tumors (UM22-NT vs UM22-XT) and 
radiation induced differences in resistant head and neck tumors (UM47-NT vs 
UM47-XT), respectively. The differences in the scores of lipid and collagen 
loadings are statistically significant (indicated by *) at p < 0.001 level (Wilcoxon 
rank sum test) for both the comparisons. The effect size (r), characterizing 




While the comparison of MCR scores provides a starting point for 
delineating the molecular mediators of treatment response/resistance and 
assessing the predictive power of the spectroscopic data, comparison of the 
individual component scores alone may not provide a robust diagnostic framework, 
especially to classify prospective samples. Therefore, we developed decision 
models based on support vector machines (SVM), a supervised classification 
method that can deal with ill-posed problems and lead to unique global models 
[33]. We conducted a leave-one-mouse-out analysis which involved training three 
separate binary SVM classifiers for each tumor type (lung and HN tumors), 
corresponding to the three sets of comparisons – RS-NT vs RS-XT, RR-NT vs RR-
XT and RS-NT vs RR-NT, respectively. RS and RR indicate radiation-sensitive and 
radiation-resistant tumor xenografts, respectively. Table 5.2 shows the aggregated 
number of mice accurately classified, unclassified, and misclassified (as 
determined by the criteria detailed in the Methods section) for each of the three 
comparisons. (The tumor model-specific decomposition is provided in Appendix 
Tables ST5.3 and ST5.4.) 
The leave-one-mouse-out protocol provides satisfactory predictions in all 
cases with an overall misclassification rate of only ca. 3%. While slightly higher 
unclassification rates were noted for the lung tumor dataset, incorporation of a 
larger cohort of animals in the HN tumor data allowed significant reduction in the 
same. In the latter set of HN tumors, slightly increased unclassification rate (albeit 
with zero misclassification) was observed for the comparison between treated 
(UM47-XT) and untreated (UM47-NT) radiation-resistant HN tumors. We attribute 
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this increased unclassification to smaller effect size observed in MCR-ALS-based 
univariate comparisons and the high classification threshold used in our leave-one-
mouse-out analysis. For example, relaxing the threshold to 80% level reduced the 
unclassification rates of comparison between UM47-NT and UM47-XT significantly 
(2/19 mice compared to 7/19 mice at 90% level). 
 
Table 5.2: Results of binary leave-one-mouse-out SVM analyses 
 Number of mice classified accurately, unclassified and 
misclassified 

































- (10+0+1)/11 - (14+1+0)/15 
 
Finally, to verify the lack of spurious correlations in the dataset [36], we 
repeated our leave-one-mouse-out analysis using the same spectral dataset, but 
with randomly assigned class labels instead of their original labels for each 
comparison. Average correct classification rate of ca. 57% for both lung tumor and 
HN tumor datasets, were obtained (comparable to the random likelihood of 
selection of the true class label – 50%). Taken together, the results of the SVM-
derived classifier model studies demonstrate the utility of the Raman spectroscopic 
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data in capturing distinct radiobiological responses in radiosensitive and 
radioresistant lung and HN tumor xenografts. 
5.4 Discussion 
A fundamental principle of personalized medicine is to design treatment strategies 
that tackle the biological heterogeneity characteristic of cancer in order to achieve 
maximal tumor control while minimizing toxicity. The lack of suitable imaging tools, 
which can identify patients unlikely to benefit from radiation and perform frequent 
response monitoring to better inform treatment doses and fractionation schemes, 
remains a major impediment in customizing radiotherapy. In contrast to existing 
clinical technologies, optical spectroscopy offers a non-invasive or minimally 
invasive route to providing real-time evaluation of treatment response based on 
functional and biomolecular changes in the tumor microenvironment. In this study, 
we demonstrate the utility of using label-free Raman spectroscopy in conjunction 
with chemometric analysis to reveal distinct biomolecular changes in radiation-
resistant and sensitive tumors when subjected to fractionated, clinically-relevant 
radiation doses. Specifically, MCR-ALS analysis reveals consistent differences in 
lipid and collagen content post-radiation in the microenvironment of lung and head 
and neck tumor xenografts with especially pronounced changes in the radiation-
sensitive cases. By leveraging SVM-derived classifiers, we are also able to 
differentiate between vibrational signatures recorded from untreated radiation-
sensitive and radiation-resistant tumors indicating the potential for future Raman 




The specific biomolecular features derived using MCR-ALS analysis have 
been previously studied in the context of cellular response to radiation. Hypoxia 
and its transcription factor, hypoxia-inducible factor (HIF-1), have been shown to 
promote extracellular matrix (ECM) remodeling and play an important role in 
promoting fibrosis [37, 38] and collagen biogenesis [39, 40]. Indeed, our recent 
investigation of cellular metabolism showed a significant increase in HIF-1α 
expression after radiation in both the A549 and rA549 cells [41]. We reason that 
the radiation-induced increase in HIF-1 content is, in part, responsible for 
promoting collagen deposition in the A549 and rA549 tumors. The increased 
collagen content may also be explained by the actions of growth factors, such as 
TGF-β, which are recruited in response to HIF-1α-stimulated macrophage 
accumulation [42]. Overexpression of TGF-β serves as a chemoattractant for the 
recruitment of fibroblasts, and may drive the increase in collagen-rich MCR scores 
upon irradiation for both sensitive and resistant tumors [43].  
Previous work has established that de novo lipogenesis protects cancer 
cells from external insults, such as oxidative stress, and that inhibition of 
lipogenesis increases oxidative stress-induced cell death [44]. The increased lipid 
content observed in both groups of radiated tumors in our study could be attributed 
to such a cellular defense mechanism in response to radiation-induced oxidative 
stress. Although the exact mechanism for increased lipid content needs further 
investigation, studies have found elevated levels of fatty acid synthase (FASN) in 
radiation-resistant HN cancer cells [45]. Furthermore, inhibition of FASN 
decreased cellular survival of these radiation-resistant cancer cells. FASN is a key 
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player in lipogenesis and has also been shown to be a prognostic indicator of 
radiation resistance in clinical nasopharyngeal carcinoma [46]. Taken together, 
these studies highlight the potential of lipids to serve as a powerful biomarker of 
radiation resistance.  
Our findings of increased glycogen content in response to radiation in the 
radiation-resistant rA549 tumors are consistent with a recent in vitro study by 
Matthews et al. that reported an increase in radiation-induced glycogen in the 
relatively radiation-resistant MCF7 breast cancer and H460 lung cancer cell lines 
[23]. Jirasek and colleagues have reported substantially increased glycogen 
content in radiated non-small cell lung tumor xenografts compared with non-
radiated xenografts [26]. However, while our study also found significantly higher 
glycogen content in the radiation-sensitive A549 tumors, Mathews and colleagues 
found no changes in glycogen content in the radiation sensitive LNCaP prostate 
cancer cells. These differences could be principally attributed to the different 
nature of the measurement specimen (cells vs. tissue). The increase in intracellular 
glycogen in their study was attributed to the phosphorylation of glycogen synthase 
kinase (GSK-3β), a negative regulator of glycogen synthase, which mediates the 
final step of glycogen synthesis. Deactivation of GSK-3β activity through 
phosphorylation has been shown to play a critical role in the acquisition of radiation 
resistance in cancer cells [47]. Although a direct role for glycogen in conferring 
protection from radiation has not been established, the availability of increased 
glycogen reserves could provide cancer cells with glucose through glycogenolysis 
during radiation-induced oxidative stress. Glucose utilization through the pentose 
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phosphate pathway can lead to the generation of glutathione, which is an important 
scavenger of radiation-induced free radicals. Our findings expand on these 
determinations by providing the first direct comparisons of glycogen levels in 
matched models of resistant and sensitive tumors. However, the smaller effect 
sizes observed in the lung tumors coupled with its absence in the HN tumors 
suggest that further investigations are necessary to evaluate the clinical utility of 
glycogen as a marker of treatment response.    
To examine the histological basis of the Raman spectroscopic 
determinations, tumor sections were stained with hematoxylin and eosin (H&E), 
Masson’s trichrome, periodic acid-Schiff (PAS) and oil red O (ORO) – for cellular 
morphology, collagen, glycogen and lipid, respectively (Fig. 5.5A-L and S5.4). 
While tumor morphology was found to be largely similar across all tumor groups, 
H&E-stained images identified high levels of necrosis as well as fibrosis in the 
tumor groups subjected to radiation therapy (XTs) compared with the untreated 
control tumors (NTs). Specifically, necrosis and fibrosis were found in all groups, 
and were correlated, with an increase in necrosis associated with an increase in 
fibrosis. Specifically, within the lung tumor group, the A549-NT and rA549-NT 
tumors demonstrated higher tumor burdens and lower levels of necrosis and 
fibrosis. Within the HN tumor group, the lowest levels of necrosis were observed 
in the 22B-NT tumors while the highest levels were observed in the 47-XT group. 
Both 22B-XT and 47-NT had similar and intermediate levels of necrosis and 
fibrosis. This is likely due to the bulkier tumors observed in the 47-NT group. This 
tumor overgrowth is often associated with a degenerative type of necrosis 
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secondary to ischemia. These histopathological results were largely consistent 
with the findings from Raman spectral analysis. Furthermore, using bright field 
images of the Masson’s trichrome and PAS stained slides, we observed increased 
levels of collagen and glycogen after radiation in both the sensitive and resistant 
tumors. In addition, collagen content was noticeably higher in the resistant tumors 
prior to radiation compared with the sensitive tumors. The histological images for 
the HN tumors have been provided in Fig. S5.4 (Appendix).  
 
 
Figure 5.5: Histologic assessment of radiation sensitivity and resistance. Top 
(A–D), middle (E–H) bottom (I-L) panels display representative microscopic 
images of H&E, Masson's trichrome and PAS stained slides, respectively. The 
columns of panels from left to right - (A, E and I), (B, F and J), (C, G and K) and 
(D, H and L), respectively, represent fields of view from tumors belonging to the 
treatment groups - A549-NT, A549-XT, rA549-NT and rA549-XT. The scale bars 




 In summary, we have used Raman spectroscopic mapping for quantitative 
assessment of the molecular composition of lung and HN tumors subjected to 
radiation therapy, and shown that such measurements offer a reliable, non-
perturbative method to probe radiation-induced alterations. These findings 
represent, to the best of our knowledge, the first report comparing the 
microenvironmental response to radiation in tumor xenografts from different organ 
sites using optical spectroscopy. Together, our results provide promising evidence 
for the clinical translation of Raman spectroscopy to discern molecular markers of 
radiation response either prior to or during the early stages of treatment using fiber 
optic probes in accessible tumors. 
Towards that goal, there are two major focal points of our future 
investigations. First, the clinical radiation dose of 2 Gy that was used in this study 
will be delivered on successive days as is usually performed in the clinic. The 
treatment regimen used here is similar to previous approaches used to establish 
radiation sensitivity and resistance in tumor xenograft models [28]. Second, 
radiation-induced microenvironmental changes were evaluated ex vivo from 
excised tumors. Our evaluation of differences related to intrinsic radiation 
resistance were conducted on the untreated control tumors. While we observed 
appreciable differences between the A549-NT and rA549-NT tumors that can be 
attributed to radiation resistance, these results do not exactly predict if these 
tumors would go on to respond or fail treatment. The results presented here 
provide an opportunity to further explore the prediction of long-term treatment 
response based on measurements made prior to commencing treatment in 
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radiation-naïve tumors in vivo. Our next study would involve in vivo pre-treatment 
measurements on tumors as well continuous measurements during treatment 
administered on successive days to enable longitudinal treatment monitoring. Our 
recent work using diffuse reflectance spectroscopy identified changes in tumor 
oxygenation in the A549 and rA549 tumors within 48 hours post-radiation; however, 
minimal or no differences in oxygenation were observed at the time of tumor 
excision [48]. Therefore, it is possible that the magnitude of radiation-induced 
biomolecular changes, as sensed by in vivo Raman measurements, will be greater 
immediately after radiation therapy. Moreover, the fabrication of appropriate 
probes [49] as well as the emergence of vibrational spectroscopic imaging systems 
that are already being adopted in clinical studies [50] indicate that translation of 
our proposed approach is feasible. Hence, based on our current findings as well 
as these technological developments, we envision that Raman measurements will 
be employed in the near future to guide treatment planning based on the inclusion 






Figure S5.1: Tumor growth assays in response to radiation therapy. For (A) 
HNSCC tumors and (B) Lung tumors. Tumors in the XT group were radiated using 
the radiation schedule described in the methods section (4 x 2 Gy) at tumor 
volumes between 100 – 200 mm3. NT groups received sham radiation. There were 
significant differences in tumor volume between NT and XT groups in the UM-
SCC-22B and A549 tumors. Differences in tumor volume were evaluated 35-50 
days post-treatment. * indicates significant differences at p < 0.05. 
 
 
Figure S5.2: Complete set of MCR-derived pure component spectra. The 
complete set of MCR-derived pure component spectra are provided here for – (A) 
lung tumor, and (B) head and neck tumor datasets. The biological components of 
interest, whose pure spectra resembles those obtained through MCR-ALS 




Figure S5.3: Heterogeneity in biochemical composition of tumors. Top (A–D) 
and middle (E–H) panels display representative MCR-ALS score maps of 
glycogen-rich and lipid-rich loadings respectively in lung and HN tumors. The 
columns of panels from left to right - (A and E), (B and F), (C and G) and (D and 
H), respectively, represent fields of view from tumors belonging to the treatment 
groups - RR-NT, RR-XT, RS-NT and RS-XT, where RR and RS are the radiation 
resistant and radiation sensitive groups respectively. Each pixel in the images in 
panels A-F spans an area of 1mm x 1mm. The bottom (I and J) panels show 
distributional homogeneity index plots calculated using relevant MCR-ALS loading 




Figure S5.4: Histologic assessment for head and neck tumor dataset. Top 
(A–D), middle (E–H) and bottom (I–L) panels display representative microscopic 
images of H&E, Masson's trichrome, and Oil Red O stained slides, respectively. 
The columns of panels from left to right - (A and I), (B and F), (C and G) and (D 
and H), respectively, represent fields of view from tumors belonging to the 
treatment groups – UM22-NT, UM22-XT, UM47-NT and UM47-XT. The scale bars 





Table ST5.1: Table listing the peak assignments for all the MCR-derived 
component spectra derived from lung tumor dataset 
 
Observed Raman peaks in the MCR 
loadings (cm-1) 
Raman band assignment 
from literature 
B1 B2 B3 B4 B5 B6 B7  
 708      Glycogen 
  790     O-P-O stretching in DNA 
  812   816  
O-P-O stretching in DNA 
and RNA  
   851    
C-C stretch of proline in 
collagen 
      878 
C-C stretch of 
hydroxyproline in collagen 
    908   
Formalin contamination 
during tissue fixation 
   928    
C-C vibration in collagen 
backbone 
 940      Glycogen 
   1040    Proline in collagen 
    1042   
Formalin contamination 
during tissue fixation 
 1044      Glycogen 
      1047 Proline in collagen 
 1078      Glycogen 
1078       C-C stretch 
  1082   1080  
PO2- symmetric stretching in 
DNA 
  1237     
PO2- asymmetric stretching 
in DNA 
     1242  Amide III in collagen 
   1251    Amide III in collagen 
    1251   
Formalin contamination 
during tissue fixation 
 1256      Glycogen 
      1259 Amide III in collagen 
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1266       
CH2 in-plane deformation 
(Triglyceride) 
1301       CH vibration (Triglyceride) 
 1320      Glycogen 
   1315    
CH3CH2 twisting modes of 
collagen 
     1337  
CH3CH2 wagging modes of 
collagen and nucleic acids 
1442       
CH2 bending mode 
(Triglyceride) 
   1453   1448 
CH2 bending mode in 
collagen 
    1489   
Formalin contamination 
during tissue fixation 
1654       C=C lipid stretch 
   1661  1657 1656 
α-helical structure of amide I 







Table ST5.2: Table listing the peak assignments for all the MCR-derived 
component spectra derived from head and neck tumor dataset 
Observed Raman peaks in the MCR 
loadings (cm-1) 
Raman band assignment 
from literature 
C1 C2 C3 C4 C5 C6 C7  
 790      O-P-O stretching in DNA 
 806      
O-P-O stretching in DNA 
and RNA  
    820   
O-P-O stretching in DNA 
and RNA 
  852     
C-C stretch of proline in 
collagen 
     873  
C-C stretch of 
hydroxyproline in collagen 
   906    
Formalin contamination 
during tissue fixation 
  932     
C-C vibration in collagen 
backbone 
  1038     Proline in collagen 
   1042    
Formalin contamination 
during tissue fixation 
     1047  Proline in collagen 
1078       C-C stretch 
 1076   1076  1074 
PO2- symmetric stretching in 
DNA 
    1235   Amide III in collagen 
  1245     Amide III in collagen 
   1256    
Formalin contamination 
during tissue fixation 
    1259 1262  Amide III in collagen 
1266       
CH2 in-plane deformation 
(Triglyceride) 
1302       CH vibration (Triglyceride) 
   1304    
Formalin contamination 
during tissue fixation 
       




  1338    1335 
CH3CH2 wagging modes of 
collagen and nucleic acids 
1442       
CH2 bending mode 
(Triglyceride) 
  1454   1448  
CH2 bending mode in 
collagen 
   1451    
Formalin contamination 
during tissue fixation 
   1491    
Formalin contamination 
during tissue fixation 
1654       C=C lipid stretch 
  1668   1657  
α-helical structure of amide I 




Table ST5.3: Results of binary leave-one-mouse-out SVM analysis for lung 
tumor dataset 
 
Number of mice classified accurately, 
unclassified and misclassified 









































Table ST5.4: Results of binary leave-one-mouse-out SVM analysis for head 
and neck tumor dataset 
 
Number of mice classified accurately, 
unclassified and misclassified 
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Thesis summary and future directions 
  
6.1 Thesis summary    
The studies presented in this thesis show that label-free Raman spectroscopy can 
take advantage of its synergistic combinations with advancements in 
nanotechnology and the growing number of multivariate data analysis tools, 
including but not limited to machine learning, for quantitative molecular 
characterization of cancer.  
Our SHINERS investigation reported in Chapter 2 revealed that while the 
enhancement of signal resulted in lower acquisition time, higher accuracy of 
prediction using the PLS-DA derived detection algorithm and better contrast 
between closely related pathologies, spontaneous Raman spectroscopy also 
provided encouraging results across the classes studied. By separately analyzing 
the data from the sites that harbored microcalcifications, we found that these 
samples provided higher classification accuracies using SHINERS and 
spontaneous Raman in comparison to those that didn’t harbor microcalcifications. 
Overall, the studies in this chapter showed that SHINERS can provide a route for 
rapid label-free disease diagnosis and subtyping in clinical samples or margin 
assessment during tissue conserving surgeries. 
 
This chapter is partially adapted from the published encyclopedia article: Paidi SK, Pandey R and 




The studies in Chapter 3 helped identify Osteopontin (OPN) as a key driver 
of the microcalcification and metastasis in breast cancer. By stable shRNA 
knockdown of the OPN gene in the aggressive MBA-MB-231 breast cancer cells 
and alizarin red S staining for microcalcifications, we showed a significant 
reduction in the stain intensity and OPN mRNA expression levels in the OPN 
silenced clones in comparison to the empty-vector control cells. The OPN silenced 
clones also exhibited a significant reduction in their in vitro migration potential. 
Furthermore, these observations were supported by elevated OPN levels in the 
circulating tumor cells and lung metastatic cells in vivo. Taken together, our studies 
in this chapter hinted at a dual role of OPN in directing microcalcification formation 
and cell migration. 
In Chapter 4, we showed that Raman spectroscopy can identify pre-
metastatic changes in the lung of mice bearing breast cancer xenografts. We used 
principal component analysis to identify spectral markers indicative of changes in 
collagen and proteoglycan content of the ECM in pre-metastatic lungs and noted 
that the changes scale with metastatic potential of the primary tumor. These 
observations were corroborated using histology and gene expression analysis. 
Finally, our classification routine based on partial least squares-discriminant 
analysis allowed the identification of an inadequately primed animal. Overall, our 
studies showed that Raman spectroscopy can be a valuable addition to the arsenal 
of current tools used for studying the composition and evolution of pre-metastatic 
niches in secondary organs. 
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Finally, in Chapter 5, we extend our Raman investigations to study the 
response of tumors to radiation therapy and predict resistance to therapy. We 
employed sensitive and resistant variants of isogenic lung cancer cells and head 
and neck cancer cells to grow tumors in athymic nude mice and subjected them to 
X-ray therapy at clinically relevant fractionated doses and sham radiation. By 
subjecting the Raman spectra obtained from irradiated and unirradiated tumors to 
multivariate curve resolution-alternating least squares, we found significant model-
specific compositional differences in the tumor microenvironment between 
irradiated and unirradiated samples for both sensitive and resistant tumors. 
Additionally, we built classifiers based on support vector machine (SVM) to assess 
the utility of Raman spectra data for prediction of response and resistance to 
radiation therapy. 
Overall, our studies pave the way for establishing Raman spectroscopy as 
a tool for both clinical decision-making in cancer care and unraveling molecular 
mechanisms underlying disease progression. 
 
6.2 Future work 
To date, several proof-of-principle studies using Raman spectroscopy have been 
conducted to understand a range of diseases and their progression both in vivo 
and ex vivo. However, the widespread clinical translation of this attractive 
technology requires further improvements in the following areas. First, inclusion of 
larger patient cohort for each application is critical for development of robust 
classification models that can effectively capture inter-patient variability. As a next 
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step in this direction, standardizing protocols for acquisition of Raman spectral 
datasets from clinical samples will help compare the results obtained by various 
groups and potentially merge them into larger datasets. Second, translation of 
SERS technologies in vivo will require additional tests to confirm their toxicity and 
accumulation in human body. However, such studies are challenging due to use 
of a variety of synthesis protocols, reporter molecules, capping agents, buffers, 
coatings and surface functionalization by different research groups. Thirdly, 
uniform metrics of success such as accuracy, sensitivity, specificity and statistical 
power must be defined by clinicians to compare and select spectroscopic protocols 
that are suitable for clinical translation. To accomplish this step, Raman 
spectroscopy and other emerging optical techniques must be introduced in medical 
education to promote awareness and enthusiasm among clinicians about this 
emerging suite of techniques. Such efforts are expected to promote more active 
collaborations between clinicians and spectroscopists. 
In addition to clinical diagnostics, Raman spectroscopy and its variants (SERS in 
particular) are rapidly emerging as important tools for discovery of molecular 
markers that characterize differences between different diseased states along 
novel axes. The preliminary spectral markers obtained from analysis of Raman 
datasets can potentially yield a narrow subset of biomolecules to be employed as 
targets for future studies using conventional wet chemistry approaches. Similarly, 
studies that have attempted to combine Raman spectroscopy with other optical 
spectroscopy techniques such as autofluorescence, diffuse reflectance 
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spectroscopy and optical coherence tomography have shown promise for 
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